

CPC COOPERATIVE PATENT CLASSIFICATION

C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material [A01N 63/00](#); food compositions [A21](#), [A23](#); medicinal preparations [A61K](#); chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles [A61L](#); fertilisers [C05](#)); **PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS** (preservation of living parts of humans or animals [A01N 1/02](#)); **MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA** (micro-biological testing media [C12Q](#))

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class [C12](#).
3. When classifying in this group, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.

WARNING

The following IPC groups are not used in the CPC scheme. Subject matter covered by these groups is classified in the following CPC groups:

C12N 1/11	covered by	C12N 15/79
C12N 1/13	covered by	C12N 15/79
C12N 1/15	covered by	C12N 15/80
C12N 1/19	covered by	C12N 15/81
C12N 1/21	covered by	C12N 15/74
C12N 5/02	covered by	C12N 5/00 , C12N 5/04 - C12N 5/166
C12N 5/07 - C12N 5/095	covered by	C12N 5/06 and subgroups
C12N 5/18 - C12N 5/28	covered by	C12N 5/16 and subgroups
C12N 5/18	covered by	C12N 5/16
C12N 5/20	covered by	C12N 5/163
C12N 5/22	covered by	C12N 5/16
C12N 5/24	covered by	C12N 5/163
C12N 5/26	covered by	C12N 5/166
C12N 5/28	covered by	C12N 5/166
C12N 7/01	covered by	C12N 7/00
C12N 9/26	covered by	C12N 9/2408
C12N 9/38	covered by	C12N 9/2468
C12N 9/42	covered by	C12N 9/2434
C12N 9/44	covered by	C12N 9/2451
C12N 9/70	covered by	C07K 14/3153
C12N 15/05	covered by	C12N 5/14
C12N 15/06	covered by	C12N 5/16
C12N 15/07	covered by	C12N 5/16
C12N 15/08	covered by	C12N 5/166
C12N 15/12	covered by	C07K 14/435
C12N 15/13	covered by	C07K 16/00
C12N 15/14	covered by	C07K 14/765
C12N 15/15	covered by	C07K 14/81
C12N 15/16	covered by	C07K 14/575
C12N 15/17	covered by	C07K 14/62
C12N 15/18	covered by	C07K 14/61
C12N 15/19	covered by	C07K 14/52
C12N 15/20	covered by	C07K 14/555
C12N 15/21	covered by	C07K 14/56
C12N 15/22	covered by	C07K 14/565
C12N 15/23	covered by	C07K 14/57
C12N 15/24	covered by	C07K 14/54
C12N 15/25	covered by	C07K 14/545
C12N 15/26	covered by	C07K 14/55
C12N 15/27	covered by	C07K 14/53

C12N 15/28	covered by	C07K 14/525
C12N 15/29	covered by	C07K 14/415
C12N 15/30	covered by	C07K 14/44
C12N 15/31	covered by	C07K 14/195 , C07K 14/005
C12N 15/32	covered by	C07K 14/325
C12N 15/33	covered by	C07K 14/005
C12N 15/34	covered by	C07K 14/01
C12N 15/35	covered by	C07K 14/015
C12N 15/36	covered by	C07K 14/02
C12N 15/37	covered by	C07K 14/025
C12N 15/38	covered by	C07K 14/03
C12N 15/39	covered by	C07K 14/065
C12N 15/40	covered by	C07K 14/08
C12N 15/41	covered by	C07K 14/085
C12N 15/42	covered by	C07K 14/09
C12N 15/43	covered by	C07K 14/105
C12N 15/44	covered by	C07K 14/11
C12N 15/45	covered by	C07K 14/115
C12N 15/46	covered by	C07K 14/14
C12N 15/47	covered by	C07K 14/145
C12N 15/48	covered by	C07K 14/15
C12N 15/49	covered by	C07K 14/155
C12N 15/50	covered by	C07K 14/165
C12N 15/51	covered by	C07K 14/02 , C07K 14/10 , C07K 14/18
C12N 15/53	covered by	C12N 9/02
C12N 15/54	covered by	C12N 9/10
C12N 15/55	covered by	C12N 9/14
C12N 15/56	covered by	C12N 9/24
C12N 15/57	covered by	C12N 9/48
C12N 15/58	covered by	C12N 9/6456
C12N 15/59	covered by	C12N 9/6483
C12N 15/60	covered by	C12N 9/88
C12N 15/61	covered by	C12N 9/90
C12N 15/83	covered by	C12N 15/82
C12N 15/84	covered by	C12N 15/82

1/00	Micro-organisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from micro-organisms A61K 35/66; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines A61K 39/00); Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor	1/20	• Bacteria ((bacteria per se C12R 1/01 - C12R 1/64)); Culture media therefor
		1/22	• Processes using, or culture media containing, cellulose or hydrolysates thereof
		1/24	• Processes using, or culture media containing, waste sulfite liquor
		1/26	• Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using micro-organisms C10G 32/00)
1/005	• {after treatment of microbial biomass not covered by C12N 1/02 - C12N 1/08 }	1/28	• . aliphatic
1/02	• Separating micro-organisms from their culture media	1/30	• . . having five or less carbon atoms
1/04	• Preserving or maintaining viable micro-organisms (immobilised micro-organisms C12N 11/00)	1/32	• Processes using, or culture media containing, lower alkanols, i.e. C ₁ to C ₆
1/06	• Lysis of micro-organisms	1/34	• Processes using foam culture
1/063	• . {of yeast}	1/36	• Adaptation or attenuation of cells
1/066	• . {by physical methods}	1/38	• Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence)
1/08	• Reducing the nucleic acid content		
1/10	• Protozoa; Culture media therefor		
1/12	• Unicellular algae; Culture media therefor (culture of multi-cellular plants A01G ; as new plants A01H 13/00)	3/00	Spore forming or isolating processes
1/14	• Fungi (culture of mushrooms A01G 1/04 ; as new plants per se A01H 15/00 ; {fungi per se C12R 1/645 - C12R 1/885 }) Culture media therefor		
1/16	• . Yeasts; Culture media therefor		
1/18	• . . Baker's yeast; Brewer's yeast		

5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques [A01H 4/00](#))

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture ([media for specific animal cell type C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)

- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates ([for specific animal cell type C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues ([culture media C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues ([preservation of living cells or tissues A01N 1/02](#)); Not used, see subgroups}

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
 - a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
 - a "multipotent" cell is restricted to one lineage.
- "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells ([production of embryos, nuclear transfer A01K 67/027](#)); Embryoid bodies}
- 5/0604 {Whole embryos; Culture medium therefor}
- 5/0605 {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] ([embryonic germ cells C12N 5/0611](#), [induced pluripotent stem cells C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC ([induced pluripotent stem cells C12N 5/0696](#))}
- 5/0608 . . . {Germ cells ([production of embryos, nuclear transfer A01K 67/027](#)); Not used, see subgroups}
- 5/0609 {Oocytes, oogonia ([fertilised oocytes C12N 5/0604](#))}
- 5/061 {Sperm cells, spermatogonia}
- 5/0611 {Primordial germ cells, e.g. embryonic germ cells [EG]}
- 5/0612 {sorting of gametes, e.g. according to sex or motility}
- 5/0613 . . . {Cells from endocrine organs ([pancreas C12N 5/0676](#), [gonads C12N 5/0681](#))}
- 5/0614 {Adrenal gland}
- 5/0615 {Pineal gland}
- 5/0616 {Pituitary gland}
- 5/0617 {Thyroid and parathyroid glands}
- 5/0618 . . . {Cells of the nervous system}
- 5/0619 {Neurons}
- 5/062 {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- 5/0621 {Eye cells, e.g. cornea, iris pigmented cells ([photoreceptors C12N 5/062](#))}
- 5/0622 {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- 5/0623 {Stem cells}

5/0625	. . . {Epidermal cells, skin cells; Cells of the oral mucosa}	5/0666 {Mesenchymal stem cells from hair follicles}
5/0626 {Melanocytes}	5/0667 {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
5/0627 {Hair cells}	5/0668 {Mesenchymal stem cells from other natural sources}
5/0628 {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)}	5/0669 {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)}
5/0629 {Keratinocytes; Whole skin}	5/067	. . . {Hepatocytes}
5/063 {Keratinocyte stem cells; Keratinocyte progenitors}	5/0671 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0631 {Mammary cells}	5/0672 {Stem cells; Progenitor cells; Precursor cells; Oval cells}
5/0632 {Cells of the oral mucosa}	5/0676	. . . {Pancreatic cells}
5/0633 {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}	5/0677 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0634	. . . {Cells from the blood or the immune system}	5/0678 {Stem cells; Progenitor cells; Precursor cells}
NOTE		5/0679	. . . {Cells of the gastro-intestinal tract}
Committed progenitors are classified with their progeny		5/068 {Stem cells; Progenitors}
5/0635 {B lymphocytes}	5/0681	. . . {Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups}
5/0636 {T lymphocytes}	5/0682 {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)}
5/0637 {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}	5/0683 {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)}
5/0638 {Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]}	5/0684	. . . {Cells of the urinary tract or kidneys}
5/0639 {Dendritic cells, e.g. Langerhans cells in the epidermis}	5/0685 {Bladder epithelial cells}
5/064 {Immunosuppressive dendritic cells}	5/0686 {Kidney cells}
5/0641 {Erythrocytes}	5/0687 {Renal stem cells; Renal progenitors}
5/0642 {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}	5/0688	. . . {Cells from the lungs or the respiratory tract}
5/0643 {Osteoclasts}	5/0689 {Stem cells; Progenitors}
5/0644 {Platelets; Megakaryocytes}	5/069	. . . {Vascular Endothelial cells}
5/0645 {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}	5/0691 {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
5/0646 {Natural killers cells [NK], NKT cells}	5/0692 {Stem cells; Progenitor cells; Precursor cells}
5/0647 {Haematopoietic stem cells; Uncommitted or multipotent progenitors}	5/0693	. . . {Tumour cells; Cancer cells}
5/0648 {Splenocytes}	5/0694 {Cells of blood, e.g. leukemia cells, myeloma cells}
5/065 {Thymocytes}	5/0695 {Stem cells; Progenitor cells; Precursor cells}
5/0651 {Lymph nodes}	5/0696	. . . {Artificially induced pluripotent stem cells, e.g. iPS}
5/0652	. . . {Cells of skeletal and connective tissues; Mesenchyme}	5/0697	. . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)}
5/0653 {Adipocytes; Adipose tissue}	5/0698	. . . {Skin equivalents}
5/0654 {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}	5/10	. Cells modified by introduction of foreign genetic material {Not used, see subgroups}
5/0655 {Chondrocytes; Cartilage}	5/12	. . Fused cells, e.g. hybridomas
5/0656 {Adult fibroblasts}	5/14	. . . Plant cells
5/0657 {Cardiomyocytes; Heart cells}	5/16	. . . Animal cells
5/0658 {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}	5/163 {one of the fusion partners being a B or a T lymphocyte}
5/0659 {Satellite cells}	5/166 {resulting from interspecies fusion}
5/066 {Tenocytes; Tendons, Ligaments}		
5/0661 {Smooth muscle cells}		
5/0662 {Stem cells}		
5/0663 {Bone marrow mesenchymal stem cells (BM-MSc)}		
5/0664 {Dental pulp stem cells, Dental follicle stem cells}		
5/0665 {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}		

7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody composition, e.g. virus vaccines, [A61K 39/00](#))

WARNING

From March 15, 2012 groups [C12N 7/02](#) - [C12N 7/08](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#).

- 7/02 . Recovery or purification
- 7/025 . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- 7/04 . Inactivation or attenuation; Producing viral sub-units
- 7/045 . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- 7/06 . . {Inactivation or attenuation} by chemical treatment
- 7/08 . . {Inactivation or attenuation} by serial passage of virus

9/00 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth [A61K 8/66](#), [A61Q 11/00](#); medicinal preparations containing enzymes or pro-enzymes [A61K 38/43](#); enzyme containing detergent compositions [C11D](#); {enzymes with nucleic acid structure, e.g. ribozymes, [C12N 15/113](#)}); **Processes for preparing, activating, inhibiting, separating or purifying enzymes** (preparation of malt [C12C 1/00](#))

NOTE

Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

- 9/0002 . {Antibodies with enzymatic activity, e.g. abzymes}
- 9/0004 . {Oxidoreductases (1.)}
- 9/0006 . . {acting on CH-OH groups as donors (1.1)}
- 9/0008 . . {acting on the aldehyde or oxo group of donors (1.2)}
- 9/001 . . {acting on the CH-CH group of donors (1.3)}
- 9/0012 . . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}
- 9/0014 . . . {acting on the CH-NH₂ group of donors (1.4)}
- 9/0016 {with NAD or NADP as acceptor (1.4.1)}
- 9/0018 {Phenylalanine dehydrogenase (1.4.1.20)}
- 9/002 {with a cytochrome as acceptor (1.4.2)}
- 9/0022 {with oxygen as acceptor (1.4.3)}
- 9/0024 {D-Amino acid oxidase (1.4.3.3)}
- 9/0026 . . . {acting on CH-NH groups of donors (1.5)}
- 9/0028 {with NAD or NADP as acceptor (1.5.1)}
- 9/003 {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- 9/0032 {with oxygen as acceptor (1.5.3)}
- 9/0034 {Sarcosine oxidase (1.5.3.1)}
- 9/0036 . . . {acting on NADH or NADPH (1.6)}
- 9/0038 {with a heme protein as acceptor (1.6.2)}
- 9/004 {Cytochrome-b5 reductase (1.6.2.2)}

- 9/0042 {NADPH-cytochrome P450 reductase (1.6.2.4)}
- 9/0044 . . . {acting on other nitrogen compounds as donors (1.7)}
- 9/0046 {with oxygen as acceptor (1.7.3)}
- 9/0048 {Uricase (1.7.3.3)}
- 9/0051 . . {acting on a sulfur group of donors (1.8)}
- 9/0053 . . {acting on a heme group of donors (1.9)}
- 9/0055 . . {acting on diphenols and related substances as donors (1.10)}
- 9/0057 . . . {with oxygen as acceptor (1.10.3)}
- 9/0059 {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
- 9/0061 {Laccase (1.10.3.2)}
- 9/0063 {Ascorbate oxidase (1.10.3.3)}
- 9/0065 . . {acting on hydrogen peroxide as acceptor (1.11)}
- 9/0067 . . {acting on hydrogen as donor (1.12)}
- 9/0069 . . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- 9/0071 . . {acting on paired donors with incorporation of molecular oxygen (1.14)}
- 9/0073 . . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- 9/0075 {Nitric-oxide synthase (1.14.13.39)}
- 9/0077 . . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
- 9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
- 9/0081 {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}
- 9/0083 . . . {Miscellaneous (1.14.99)}
- 9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}
- 9/0087 {Steroid 21-monooxygenase (1.14.99.10)}
- 9/0089 . . {acting on superoxide as acceptor (1.15)}
- 9/0091 . . {oxidizing metal ions (1.16)}
- 9/0093 . . {acting on CH or CH₂ groups (1.17)}
- 9/0095 . . {acting on iron-sulfur proteins as donor (1.18)}
- 9/0097 . . {acting on reduced flavodoxin as donor (1.19)}
- 9/10 . Transferases (2.) ([ribonucleases C12N 9/22](#))
- 9/1003 . . {transferring one-carbon groups (2.1)}
- 9/1007 . . . {Methyltransferases (general) (2.1.1.)}
- 9/1011 {Catechol O-methyltransferase (2.1.1.6)}
- 9/1014 {Hydroxymethyl-, formyl-transferases (2.1.2)}
- 9/1018 {Carboxy- and carbamoyl transferases (2.1.3)}
- 9/1022 . . {transferring aldehyde or ketonic groups (2.2)}
- 9/1025 . . {Acyltransferases (2.3)}
- 9/1029 . . . {transferring groups other than amino-acyl groups (2.3.1)}
- 9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}
- 9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
- 9/104 . . . {Aminoacyltransferases (2.3.2)}
- 9/1044 {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
- 9/1048 . . {Glycosyltransferases (2.4)}
- 9/1051 . . . {Hexosyltransferases (2.4.1)}
- 9/1055 {Levansucrase (2.4.1.10)}
- 9/1059 {Cellulose synthases (2.4.1.12; 2.4.1.29)}
- 9/1062 {Sucrose synthase (2.4.1.13)}
- 9/1066 {Sucrose phosphate synthase (2.4.1.14)}

9/107 {1,4-Alpha-glucan branching enzyme (2.4.1.18)}	9/2431 {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
9/1074 {Cyclomaltodextrin glucanotransferase (2.4.1.19)}	9/2434 {acting on beta-1,4-glucosidic bonds}
9/1077	. . . {Pentosyltransferases (2.4.2)}	9/2437 {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
9/1081	. . . {transferring other glycosyl groups (2.4.99)}	9/244 {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}	9/2442 {Chitinase (3.2.1.14)}
9/1088	. . . {Glutathione transferase (2.5.1.18)}	9/2445 {Beta-glucosidase (3.2.1.21)}
9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	9/2448 {Licheninase (3.2.1.73)}
9/1096	. . {transferring nitrogenous groups (2.6)}	9/2451 {acting on alpha-1,6-glucosidic bonds}
9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)	9/2454 {Dextranase (3.2.1.11)}
9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	9/2457 {Pullulanase (3.2.1.41)}
9/1211 {Thymidine kinase (2.7.1.21)}	9/246 {Isoamylase (3.2.1.68)}
9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	9/2462 {Lysozyme (3.2.1.17)}
9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	9/2465 {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}	9/2468 {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
9/1235	. . . {Diphosphotransferases (2.7.6)}	9/2471 {Beta-galactosidase (3.2.1.23), i.e. exo-(1->4)-beta-D-galactanase}
9/1241	. . . {Nucleotidyltransferases (2.7.7)}	9/2474 {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
9/1247 {DNA-directed RNA polymerase (2.7.7.6)}	9/2477 {Hemicellulases not provided in a preceding group}
9/1252 {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}	9/248 {Xylanases}
9/1258 {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}	9/2482 {Endo-1,4-beta-xylanase (3.2.1.8)}
9/1264 {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}	9/2485 {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
9/127 {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}	9/2488 {Mannanases}
9/1276 {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}	9/2491 {Beta-mannosidase (3.2.1.25), i.e. mannanase}
9/1282 {RNA uridylyltransferase (2.7.7.52)}	9/2494 {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}	9/2497	. . . {hydrolysing N- glycosyl compounds (3.2.2)}
9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}	9/48	. . acting on peptide bonds (3.4)
9/13	. . {transferring sulfur containing groups (2.8)}	9/485	. . . {Exopeptidases (3.4.11-3.4.19)}
9/14	. Hydrolases (3)	9/50	. . . Proteinases {Endopeptidases (3.4.21-3.4.25)}
9/16	. . acting on ester bonds (3.1)	9/503 {derived from viruses}
9/18	. . . Carboxylic ester hydrolases {(3.1.1)}	9/506 {derived from RNA viruses}
9/20 Triglyceride splitting, e.g. by means of lipase	9/52 derived from bacteria
9/22	. . . Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)}	9/54 bacteria being Bacillus
9/24	. . acting on glycosyl compounds (3.2)	9/58 derived from fungi
9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}	9/60 from yeast
9/2405 {Glucanases}	9/62 from Aspergillus
9/2408 {acting on alpha -1,4-glucosidic bonds}	9/63 {derived from plants}
9/2411 {Amylases}	9/64 derived from animal tissue
9/2414 {Alpha-amylase (3.2.1.1.)}	9/6402 {from non-mammals}
9/2417 {from microbiological source}	9/6405 {not being snakes}
9/242 {Fungal source}	9/6408 {Serine endopeptidases (3.4.21)}
9/2422 {from plant source}	9/641 {Cysteine endopeptidases (3.4.22)}
9/2425 {Beta-amylase (3.2.1.2)}	9/6413 {Aspartic endopeptidases (3.4.23)}
9/2428 {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}	9/6416 {Metalloendopeptidases (3.4.24)}
		9/6418 {from snakes}
		9/6421 {from mammals}
		9/6424 {Serine endopeptidases (3.4.21)}
		9/6427 {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
		9/6429 {Thrombin (3.4.21.5)}
		9/6432 {Coagulation factor Xa (3.4.21.6)}
		9/6435 {Plasmin (3.4.21.7), i.e. fibrinolysin}
		9/6437 {Coagulation factor VIIa (3.4.21.21)}

9/644	{Coagulation factor IXa (3.4.21.22)}	11/02	. Enzymes or microbial cells being immobilised on or in an organic carrier
9/6443	{Coagulation factor XIa (3.4.21.27)}	11/04	. . entrapped within the carrier, e.g. gel, hollow fibre
9/6445	{Kallikreins (3.4.21.34; 3.4.21.35)}	11/06	. . attached to the carrier via a bridging agent
9/6448	{Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}	11/08	. . carrier being a synthetic polymer
9/6451	{Coagulation factor XIIa (3.4.21.38)}	11/10	. . carrier being a carbohydrate
9/6454	{Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}	11/12	. . . Cellulose or derivative thereof
9/6456	{Plasminogen activators}	11/14	. Enzymes or microbial cells being immobilised on or in an inorganic carrier
9/6459	{t-plasminogen activator (3.4.21.68), i.e. tPA}	11/16	. Enzymes or microbial cells being immobilised on or in a biological cell
9/6462	{u-Plasminogen activator (3.4.21.73), i.e. urokinase}	11/18	. Multi-enzyme systems
9/6464	{Protein C (3.4.21.69)}	13/00	Treatment of micro-organisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
9/6467	{Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}	15/00	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered micro-organisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00)
9/647	{Blood coagulation factors not provided for in a preceding group or according to more than one of the preceding groups}	15/01	. Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
9/6472	{Cysteine endopeptidases (3.4.22)}	15/02	. Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K 16/00 ; apparatus for cell fusion C12M)}
9/6475	{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}	15/03	. . Bacteria
9/6478	{Aspartic endopeptidases (3.4.23)}	15/04	. . Fungi
9/6481	{Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}	15/09	. Recombinant DNA-technology
9/6483	{Chymosin (3.4.23.4), i.e. rennin}	15/10	. . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00 ; preparation of non-structural polynucleotides from micro-organisms or with enzymes C12P 19/34)
9/6486	{Renin (3.4.23.15)}		
9/6489	{Metalloendopeptidases (3.4.24)}		
9/6491	{Matrix metalloproteases (MMP's), e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}		
9/6494	{Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}		
9/6497	{Endothelin-converting enzyme (3.4.24.71)}		
9/78	. .	acting on carbon to nitrogen bonds other than peptide bonds (3.5)		
9/80	. . .	acting on amide bonds in linear amides {(3.5.1)}		
9/82	. . .	Asparaginase {(3.5.1.1)}		
9/84	. . .	Penicillin amidase {(3.5.1.11)}		
9/86	. . .	acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}		
9/88	. .	Lyases (4.)		
9/90	. .	Isomerases (5.)		
9/92	. .	Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}		
9/93	. .	{Ligases (6)}		
9/94	. .	Pancreatin	15/1003	. . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
9/96	. .	Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates	15/1006 {by means of a solid support carrier, e.g. particles, polymers}
9/98	. .	Preparation of granular or free-flowing enzyme compositions (C12N 9/96 takes precedence)	15/101 {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
9/99	. .	Enzyme inactivation by chemical treatment	15/1013 {by using magnetic beads}
11/00		Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof		

NOTE

After the symbol [C12N 15/10](#) - [C12N 15/1096](#), and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups [C12Q 2500/00](#) - [C12Q 2565/634](#), relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : [C12N 15/1037](#) + [C12Q 2537/125](#) + [C12Q 2521/537](#)

- 15/1017 {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 {[In vivo](#) mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 {SELEX}
- 15/1051 {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 {Screening libraries by altering the phenotype or phenotypic trait of the host ([reporter assays C12N 15/1086](#))}
- 15/1082 {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}
- NOTE**
- Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)
- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 {against viruses}
- 15/1132 {against retroviridae, e.g. HIV}
- 15/1133 {against herpesviridae, e.g. HSV}
- 15/1135 {against oncogenes or tumor suppressor genes}
- 15/1136 {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 {against receptors or cell surface proteins}
- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith; {Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- NOTE**
- Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound
- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes
- NOTE**
- In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

15/62	. . . DNA sequences coding for fusion proteins	15/746 {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
	NOTE		
	In this group, the following term is used with the meaning indicated:	15/75 for Bacillus
	– "fusion" means the fusion of two different proteins.	15/76 for Actinomyces; for Streptomyces
15/625 {containing a sequence coding for a signal sequence}	15/77 for Corynebacterium; for Brevibacterium
15/63	. . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression	15/78 for Pseudomonas
15/635	. . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}	15/79	. . . Vectors or expression systems specially adapted for eukaryotic hosts
15/64	. . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host		NOTE
15/65	. . . using markers (enzymes used as markers C12N 15/52)		This group <u>covers</u> the use of eukaryotes as hosts.
15/66	. . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease	15/80 for fungi
	NOTE	15/81 for yeasts
	In this group, the following expression is used with the meaning indicated:	15/815 {for yeasts other than Saccharomyces}
	– "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.	15/82 for plant cells, {e.g. plant artificial chromosomes (PACs)}
15/67	. . . General methods for enhancing the expression		WARNING
15/68 Stabilisation of the vector		Documents are being continuously reclassified into this new classification scheme. See Warning notes below
15/69 Increasing the copy number of the vector	15/8201 {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}
15/70	. . . Vectors or expression systems specially adapted for E. coli	15/8202 {by biological means, e.g. cell mediated or natural vector}
	NOTES	15/8203 {Virus mediated transformation}
	1. This group <u>covers</u> the use of E. coli as host.	15/8205 {Agrobacterium mediated transformation}
	2. Shuttle vectors also replicating in E. coli are classified according to the other host.	15/8206 {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}
15/71 Expression systems using regulatory sequences derived from the trp-operon	15/8207 {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}
15/72 Expression systems using regulatory sequences derived from the lac-operon	15/8209 {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}
15/73 Expression systems using phage (lambda) regulatory sequences		NOTE
15/74	. . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora		Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209
	NOTE	15/821 {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
	This group <u>covers</u> the use of prokaryotes as hosts.	15/8212 {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}
15/743 {for Agrobacterium; Rhizobium; Bradyrhizobium}	15/8213 {Targeted insertion of genes into the plant genome by homologous recombination}
		15/8214 {Plastid transformation}
		15/8216 {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}

15/8217	{Gene switch}	15/8251	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
15/8218	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}	15/8253	{Methionine or cysteine}
15/822	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}	15/8254	{Tryptophan or lysine}
15/8221	{Transit peptides}	15/8255	{involving lignin biosynthesis}
15/8222	{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}	15/8257	{for the production of primary gene products, e.g. pharmaceutical products, interferon}
15/8223	{Vegetative tissue-specific promoters}	15/8258	{for the production of oral vaccines (antigens) or immunoglobulins}
15/8225	{Leaf-specific, e.g. including petioles, stomata}	15/8259	{Phytoremediation}
15/8226	{Stem-specific, e.g. including tubers, beets}	15/8261	{with agronomic (input) traits, e.g. crop yield}
15/8227	{Root-specific}	15/8262	{involving plant development (not used)}
15/8229	{Meristem-specific, e.g. nodal, apical}	15/8263	{Ablation; Apoptosis}
15/823	{Reproductive tissue-specific promoters}	15/8265	{Transgene containment, e.g. gene dispersal}
15/8231	{Male-specific, e.g. anther, tapetum, pollen}	15/8266	{Abscission; Dehiscence; Senescence}
15/8233	{Female-specific, e.g. pistil, ovule}	15/8267	{Seed dormancy, germination or sprouting}
15/8234	{Seed-specific, e.g. embryo, endosperm}	15/8269	{Photosynthesis}
15/8235	{Fruit-specific}	15/827	{Flower development or morphology, e.g. flowering promoting factor [FPF]}
15/8237	{Externally regulated expression systems}	15/8271	{for stress resistance, e.g. heavy metal resistance}
15/8238	{chemically inducible, e.g. tetracycline}	15/8273	{for drought, cold, salt resistance}
15/8239	{pathogen inducible}	15/8274	{for herbicide resistance}
15/8241	{Phenotypically and genetically modified plants via recombinant DNA technology}	15/8275	{Glyphosate}
15/8242	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}	15/8277	{Phosphinotricin}
15/8243	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}	15/8278	{Sulfonylurea}
15/8245	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}	15/8279	{for biotic stress resistance, pathogen resistance, disease resistance}
15/8246	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}	15/8281	{for bacterial resistance}
15/8247	{involving modified lipid metabolism, e.g. seed oil composition}	15/8282	{for fungal resistance}
15/8249	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}	15/8283	{for virus resistance}
15/825	{involving pigment biosynthesis}	15/8285	{for nematode resistance}
			15/8286	{for insect resistance}
			15/8287	{for fertility modification, e.g. apomixis}
			15/8289	{Male sterility}
			15/829	{Female sterility}
			15/8291	{Hormone-influenced development}
			15/8293	{Absciscic acid [ABA]}
			15/8294	{Auxins}
			15/8295	{Cytokinins}
			15/8297	{Gibberellins; GA3}
			15/8298	{Brassinosteroids}
			15/85	for animal cells
			15/8509	{for producing genetically modified animals, e.g. transgenic}

NOTE

Transgenic plants with altered flower morphology are also classified in this group

NOTE

The purpose of the modified animal is indicated using the codes under [A01K 2267/00](#)

2015/8518	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
2015/8527	{for producing animal models, e.g. for tests or diseases}
2015/8536	{Animal models for genetic diseases}
2015/8545	{for Alzheimer's disease}
2015/8554	{Invertebrates models for Alzheimer's disease}
2015/8563	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
2015/8572	{Animal models for proliferative diseases, e.g. comprising an oncogene}
2015/8581	{Animal models for infectious diseases, e.g. AIDS}
2015/859	{Animal models comprising reporter system for screening tests}
15/86	Viral vectors

WARNING

From March 15, 2012 groups [C12N 15/861](#) - [C12N 15/869](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#)

15/861	Adenoviral vectors
15/8613	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
15/8616	{Special methods for targeting systems}
15/863	Poxviral vectors, {e.g. entomopoxvirus}
15/8633	{Avian poxviral vectors}
15/8636	{Vaccina virus vectors}
15/864	Parvoviral vectors, {e.g. parvovirus, densovirus}
15/8645	{Adeno-associated virus}
15/866	Baculoviral vectors
15/867	Retroviral vectors
15/8673	{Special methods for packaging systems}
15/8676	{Special methods for targeting systems}
15/869	Herpesviral vectors
15/8695	{Herpes simplex virus-based vectors}
15/87	. . .	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
15/873	. . .	Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
15/877	. . .	Techniques for producing new mammalian cloned embryos
15/8771	{Bovine embryos}
15/8772	{Caprine embryos}
15/8773	{Ovine embryos}
15/8775	{Murine embryos}

15/8776	{Primate embryos}
15/8777	{Rabbit embryos}
15/8778	{Swine embryos}
15/88	. . .	using micro-encapsulation, e.g. using {amphiphile} liposome vesicle
15/89	. . .	using micro-injection
15/895	{using biolistic methods}
15/90	. . .	Stable introduction of foreign DNA into chromosome
15/902	{using homologous recombination}
15/905	{in yeasts}
15/907	{in mammalian cells}

2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids

NOTE

Indexing codes of group [C12N 2303/00](#) are only used in combination with group [C12N 15/111](#)

2310/00 Structure or type of the nucleic acid

2310/10	. . .	Type of nucleic acid
2310/11	. . .	Antisense
2310/111	. . .	spanning the whole gene, or a large part of it
2310/113	. . .	targeting other non-coding nucleic acids, e.g. antagomirs
2310/12	. . .	catalytic nucleic acids, e.g. ribozymes
2310/121	. . .	Hammerhead
2310/122	. . .	Hairpin
2310/123	. . .	Hepatitis delta
2310/124	. . .	based on group I or II introns
2310/1241	Tetrahymena
2310/126	. . .	involving RNase P
2310/127	. . .	DNAzymes
2310/128	. . .	processing or releasing ribozyme
2310/13	. . .	Decoys
2310/14	. . .	interfering N.A.
2310/141	. . .	MicroRNAs, miRNAs
2310/15	. . .	Nucleic acids forming more than 2 strands, e.g. TFOs
2310/151	. . .	more than 3 strands, e.g. tetrads, H-DNA
2310/152	. . .	on a single-stranded target, e.g. fold-back TFOs
2310/153	. . .	with the aid of a protein, e.g. recombinase
2310/16	. . .	Aptamers
2310/17	. . .	Immunomodulatory nucleic acids
2310/18	. . .	acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
2310/30	. . .	Chemical structure
2310/31	. . .	of the backbone
2310/311	. . .	Phosphotriesters
2310/312	. . .	Phosphonates
2310/3125	Methylphosphonates
2310/313	. . .	Phosphorodithioates
2310/314	. . .	Phosphoramidates
2310/3145	with the nitrogen in 3' or 5'-position
2310/315	. . .	Phosphorothioates
2310/316	. . .	Phosphonothioates
2310/317	. . .	with an inverted bond, e.g. a cap structure
2310/318	. . .	where the PO2 is completely replaced, e.g. MMI or formacetal
2310/3181	Peptide nucleic acid, PNA

2310/3183 Diol linkers, e.g. glycols or propanediols	2320/12	. . in functional genomics, i.e. for the determination of gene function
2310/319	. . . linked by 2'-5' linkages, i.e. having a free 3'-position	2320/13	. . in a process of directed evolution, e.g. SELEX, acquiring a new function
2310/32	. . of the sugar	2320/30	. Special therapeutic applications
2310/321	. . . 2'-O-R Modification	2320/31	. . Combination therapy
2310/322	. . . 2'-R Modification	2320/32	. . Special delivery means, e.g. tissue-specific
2310/323	. . . modified ring structure	2320/33	. . Alteration of splicing
2310/3231 having an additional ring, e.g. LNA, ENA	2320/34	. . Allele or polymorphism specific uses
2310/3233 Morpholino-type ring	2320/35	. . based on a specific dosage / administration regimen
2310/3235 having the O of the ribose replaced by another atom	2320/50	. Methods for regulating/modulating their activity
2310/33	. . of the base	2320/51	. . modulating the chemical stability, e.g. nuclease-resistance
2310/331	. . . Universal or degenerate base	2320/52	. . modulating the physical stability, e.g. GC-content
2310/332	. . . Abasic residue	2320/53	. . reducing unwanted side-effects
2310/333	. . . Modified A	2330/00	Production
2310/334	. . . Modified C	2330/10	. naturally occurring
2310/3341 5-Methylcytosine	2330/30	. chemically synthesised
2310/335	. . . Modified T or U	2330/31	. . Libraries, arrays
2310/336	. . . Modified G	2330/50	. Biochemical production, i.e. in a transformed host cell
2310/337	. . . in alpha-anomeric form	2330/51	. . Specially adapted vectors
2310/34	. . Spatial arrangement of the modifications	2500/00	Specific components of cell culture medium
2310/341	. . . Gapmers, i.e. of the type =====	2500/02	. Atmosphere, e.g. low oxygen conditions
2310/342	. . . Hemimers, i.e. of the type =====	2500/05	. Inorganic components
2310/343	. . . having patterns, e.g. =====	2500/10	. . Metals; Metal chelators (cobalamine C12N 2500/38)
2310/344	. . . Position-specific modifications, e.g. on every purine, at the 3'-end	2500/12	. . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
2310/345	. . . having at least two different backbone modifications	2500/14 Calcium; Ca chelators; Calcitonin
2310/346	. . . having a combination of backbone and sugar modifications	2500/16 Magnesium; Mg chelators
2310/35	. . Nature of the modification	2500/20	. . . Transition metals
2310/351	. . . Conjugate	2500/22 Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33)
2310/3511 intercalating or cleaving agent	2500/24 Iron; Fe chelators; Transferrin
2310/3513 Protein; Peptide	2500/25 Insulin-transferrin; Insulin-transferrin-selenium
2310/3515 Lipophilic moiety, e.g. cholesterol	2500/30	. Organic components (metal chelators C12N 2500/10 ; calcitonin C12N 2500/14 ; transferrin C12N 2500/24)
2310/3517 Marker; Tag	2500/32	. . Amino acids
2310/3519 Fusion with another nucleic acid	2500/33	. . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
2310/352	. . . linked to the nucleic acid via a carbon atom	2500/34	. . Sugars
2310/3521 Methyl	2500/35	. . Polyols, e.g. glycerin, inositol
2310/3523 Allyl	2500/36	. . Lipids
2310/3525 MOE, methoxyethoxy	2500/38	. . Vitamins
2310/3527 Other alkyl chain	2500/40	. . Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01 , anti-neoplastic drugs C12N 2501/06)
2310/3529 Aromatic substituent	2500/42	. . Organic phosphate, e.g. beta glycerophosphate
2310/353	. . . linked to the nucleic acid via an atom other than carbon	2500/44	. . Thiols, e.g. mercaptoethanol
2310/3531 Hydrogen	2500/46	. . Amines, e.g. putrescine
2310/3533 Halogen	2500/50	. Soluble polymers, e.g. polyethyleneglycol [PEG]
2310/3535 Nitrogen	2500/60	. Buffer, e.g. pH regulation, osmotic pressure
2310/50	. Physical structure	2500/62	. . DMSO
2310/51	. . in polymeric form, e.g. multimers, concatemers	2500/70	. Undefined extracts (conditioned medium C12N 2502/00)
2310/52	. . branched	2500/72	. . from bacteria
2310/53	. . partially self-complementary or closed	2500/74	. . from fungi, e.g. yeasts
2310/531	. . . Stem-loop; Hairpin		
2310/532	. . . Closed or circular		
2310/533	. . . having a mismatch or nick in at least one of the strands		
2320/00	Applications; Uses		
2320/10	. in screening processes		
2320/11	. . for the determination of target sites, i.e. of active nucleic acids		

- 2500/76 . . from plants
- 2500/78 . . from protozoa
- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012.

The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

2501/00 Active agents used in cell culture processes, e.g. differentiation

NOTE

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
- 2501/05 . Adjuvants
- 2501/051 . . Lipid A (MPA, MPL)
- 2501/052 . . Lipopolysaccharides [LPS]
- 2501/054 . . Muramyl peptides
- 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
- 2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- 2501/065 . Modulators of histone acetylation
- 2501/07 . Heat shock proteins
- 2501/10 . Growth factors
- 2501/105 . . Insulin-like growth factors [IGF]
- 2501/11 . . Epidermal growth factor [EGF]
- 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
- 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)
- 2501/117 . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- 2501/119 . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- 2501/12 . . Hepatocyte growth factor [HGF]
- 2501/125 . . Stem cell factor [SCF], c-kit ligand [KL]

- 2501/13 . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- 2501/135 . . Platelet-derived growth factor [PDGF]
- 2501/14 . . Erythropoietin [EPO]
- 2501/145 . . Thrombopoietin [TPO]
- 2501/148 . . Transforming growth factor alpha [TGF- α]
- 2501/15 . . Transforming growth factor beta (TGF- β)
- 2501/155 . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- 2501/16 . . Activin; Inhibin; Mullerian inhibiting substance
- 2501/165 . . Vascular endothelial growth factor [VEGF]
- 2501/17 . . Angiopoietin
- 2501/175 . . Cardiotrophin
- 2501/18 . . Liver cell growth factor (LCGF, Gly-His-Lys)
- 2501/185 . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
- 2501/19 . . Growth and differentiation factors [GDF]
- 2501/195 . . Heregulin, neu differentiation factor
- 2501/20 . Cytokines; Chemokines
- 2501/21 . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- 2501/22 . . Colony stimulating factors (G-CSF, GM-CSF)
- 2501/23 . . Interleukins [IL]
- 2501/2301 . . . Interleukin-1 (IL-1)
- 2501/2302 . . . Interleukin-2 (IL-2)
- 2501/2303 . . . Interleukin-3 (IL-3)
- 2501/2304 . . . Interleukin-4 (IL-4)
- 2501/2305 . . . Interleukin-5 (IL-5)
- 2501/2306 . . . Interleukin-6 (IL-6)
- 2501/2307 . . . Interleukin-7 (IL-7)
- 2501/2308 . . . Interleukin-8 (IL-8)
- 2501/2309 . . . Interleukin-9 (IL-9)
- 2501/231 . . . Interleukin-10 (IL-10)
- 2501/2311 . . . Interleukin-11 (IL-11)
- 2501/2312 . . . Interleukin-12 (IL-12)
- 2501/2313 . . . Interleukin-13 (IL-13)
- 2501/2314 . . . Interleukin-14 (IL-14)
- 2501/2315 . . . Interleukin-15 (IL-15)
- 2501/2316 . . . Interleukin-16 (IL-16)
- 2501/2317 . . . Interleukin-17 (IL-17)
- 2501/2318 . . . Interleukin-18 (IL-18)
- 2501/2319 . . . Interleukin-19 (IL-19)
- 2501/232 . . . Interleukin-20 (IL-20)
- 2501/2321 . . . Interleukin-21 (IL-21)
- 2501/2322 . . . Interleukin-22 (IL-22)
- 2501/2323 . . . Interleukin-23 (IL-23)
- 2501/2324 . . . Interleukin-24 (IL-24)
- 2501/2325 . . . Interleukin-25 (IL-25)
- 2501/2326 . . . Interleukin-26 (IL-26)
- 2501/2327 . . . Interleukin-27 (IL-27)
- 2501/2328 . . . Interleukin-28 (IL-28)
- 2501/2329 . . . Interleukin-29 (IL-29)
- 2501/233 . . . Interleukin-30 (IL-30)
- 2501/2331 . . . Interleukin-31 (IL-31)
- 2501/2332 . . . Interleukin-32 (IL-32)
- 2501/2333 . . . Interleukin-33 (IL-33)
- 2501/2334 . . . Interleukin-34 (IL-34)
- 2501/2335 . . . Interleukin-35 (IL-35)
- 2501/235 . . . Leukemia inhibitory factor [LIF]

2501/237	. . Oncostatin M [OSM]	2501/72	. . Transferases (EC 2.) (acetylation of histones C12N 2501/065)
2501/24	. . Interferons [IFN]	2501/724	. . . Glycosyltransferases (EC 2.4.)
2501/25	. . Tumour necrosing factors [TNF]	2501/727	. . . Kinases (EC 2.7.)
2501/26	. . Flt-3 ligand (CD135L, flk-2 ligand)	2501/73	. . Hydrolases (EC 3.)
2501/30	. Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85)	2501/734	. . . Proteases (EC 3.4.)
2501/305	. . Growth hormone [GH], aka. somatotropin	2501/80	. Neurotransmitters; Neurohormones
2501/31	. . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins	2501/805	. . Acetylcholine
2501/315	. . Prolactin	2501/81	. . Adrenaline
2501/32	. . Angiotensins [AT], angiotensinogen	2501/815	. . Dopamine
2501/33	. . Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105)	2501/82	. . Histamine
2501/335	. . Glucagon; Glucagon-like peptide [GLP]; Exendin	2501/825	. . Serotonin (5-HT); Melatonin
2501/34	. . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin	2501/83	. . Tachykinins, e.g. substance P
2501/345	. . Gastrin; Cholecystokinins [CCK]	2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]
2501/35	. . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]	2501/84	. . Excitatory amino acids
2501/355	. . Leptin	2501/845	. . Gamma amino butyric acid [GABA]
2501/36	. . Somatostatin	2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
2501/365	. . Endothelin	2501/855	. . Corticotropin [ACTH]
2501/37	. . Parathyroid hormone [PTH]	2501/86	. . Melanocyte-stimulating hormone [MSH]
2501/375	. . Thyroid stimulating hormone [TSH]	2501/90	. Polysaccharides
2501/38	. . with nuclear receptors	2501/905	. . Hyaluronic acid
2501/385	. . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]	2501/91	. . Heparin
2501/39	. . . Steroid hormones	2501/998	. Proteins not provided for elsewhere
2501/392 Sexual steroids	NOTE	
2501/395	. . . Thyroid hormones	Classification by pathway does not apply.	
2501/40	. Regulators of development	2501/999	. Small molecules not provided for elsewhere
2501/405	. . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases	NOTE	
2501/41	. . Hedgehog proteins; Cyclopamine (inhibitor)	Classification by pathway does not apply.	
2501/415	. . Wnt; Frizzled	2502/00	Coculture with; Conditioned medium produced by
2501/42	. . Notch; Delta; Jagged; Serrate	2502/02	. embryonic cells
2501/48	. . Regulators of apoptosis	2502/025	. . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
2501/50	. Cell markers; Cell surface determinants	2502/03	. non-embryonic pluripotent stem cells
2501/505	. . CD4; CD8	2502/04	. germ cells
2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)	2502/07	. endocrine cells
2501/515	. . CD3, T-cell receptor complex	2502/072	. . adrenal cells
2501/52	. . CD40, CD40-ligand (CD154)	2502/074	. . pinealocytes
2501/53	. . CD2	2502/076	. . pituitary cells
2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)	2502/078	. . thyroid, parathyroid cells
2501/585	. . Integrins	2502/08	. cells of the nervous system
2501/59	. . Lectins	2502/081	. . neurons
2501/599	. . with CD designations not provided for elsewhere	2502/083	. . sensory transducers
2501/60	. Transcription factors	2502/085	. . eye cells
2501/602	. . Sox-2	2502/086	. . glial cells
2501/603	. . Oct-3/4	2502/088	. . neural stem cells
2501/604	. . Klf-4	2502/09	. epidermal cells, skin cells, oral mucosa cells
2501/605	. . Nanog	2502/091	. . melanocytes
2501/606	. . c-Myc	2502/092	. . hair cells
2501/608	. . Lin28	2502/094	. . keratinocytes
2501/65	. Micro-RNA	2502/095	. . mammary cells
2501/70	. Enzymes	2502/097	. . oral mucosa cells
2501/71	. . Oxidoreductases (EC 1.)	2502/098	. . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
		2502/11	. blood or immune system cells
		2502/1107	. . B cells
		2502/1114	. . T cells
		2502/1121	. . Dendritic cells

2502/1128	. . Erythrocytes
2502/1135	. . Granulocytes
2502/1142	. . Osteoclasts
2502/115	. . Platelets, megakaryocytes
2502/1157	. . Monocytes, macrophages
2502/1164	. . NK cells
2502/1171	. . Haematopoietic stem cells
2502/1178	. . Spleen cells
2502/1185	. . Thymus cells
2502/1192	. . Lymphatic cells
2502/13	. connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
2502/1305	. . Adipocytes
2502/1311	. . Osteocytes, osteoblasts, odontoblasts
2502/1317	. . Chondrocytes
2502/1323	. . Adult fibroblasts
2502/1329	. . Cardiomyocytes
2502/1335	. . Skeletal muscle cells, myocytes, myoblasts, myotubes
2502/1341	. . Tenocytes, cells from tendons and ligaments
2502/1347	. . Smooth muscle cells
2502/1352	. . Mesenchymal stem cells
2502/1358	. . . Bone marrow mesenchymal stem cells (BM- MSC)
2502/1364	. . . Dental pulp stem cells, dental follicle stem cells
2502/137	. . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
2502/1376	. . . Mesenchymal stem cells from hair follicles
2502/1382	. . . Adipose-derived stem cells [ADSC], adipose stromal stem cells
2502/1388	. . . Mesenchymal stem cells from other natural sources
2502/1394	. . Bone marrow stromal cells; whole marrow
2502/14	. hepatocytes
2502/22	. pancreatic cells
2502/23	. Gastro-intestinal tract cells
2502/24	. Genital tract cells, non-germinal cells from gonads
2502/243	. . Cells of the female genital tract, non-germinal ovarian cells
2502/246	. . Cells of the male genital tract, non-germinal testis cells
2502/25	. Urinary tract cells, renal cells
2502/253	. . Bladder cells
2502/256	. . Renal cells
2502/27	. Lung cells, respiratory tract cells
2502/28	. Vascular endothelial cells
2502/30	. tumour cells
2502/45	. Artificially induced pluripotent stem cells
2502/50	. invertebrate cells
2502/70	. Non-animal cells
2502/99	. genetically modified cells

NOTE

Use [C12N 2501/00](#) to index the expressed products.

2503/00 Use of cells in diagnostics

2503/02	. Drug screening
2503/04	. Screening or testing on artificial tissues
2503/06	. . Screening or testing on artificial skin

2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells**NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02	. from embryonic cells
2506/025	. . from extra-embryonic cells, e.g. trophoblast, placenta
2506/03	. from non-embryonic pluripotent stem cells
2506/04	. from germ cells
2506/07	. from endocrine cells
2506/072	. . from adrenal cells
2506/074	. . from pinealocytes
2506/076	. . from pituitary cells
2506/078	. . from thyroid, parathyroid cells
2506/08	. from cells of the nervous system
2506/09	. from epidermal cells, from skin cells, from oral mucosa cells
2506/091	. . from melanocytes
2506/092	. . from hair cells
2506/094	. . from keratinocytes
2506/095	. . from mammary cells
2506/097	. . from oral mucosa cells
2506/098	. . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2506/11	. from blood or immune system cells
2506/115	. . from monocytes, from macrophages
2506/13	. from connective tissue cells, from mesenchymal cells
2506/1307	. . from adult fibroblasts
2506/1315	. . from cardiomyocytes
2506/1323	. . from skeletal muscle cells
2506/133	. . from tenocytes
2506/1338	. . from smooth muscle cells
2506/1346	. . from mesenchymal stem cells
2506/1353	. . . from bone marrow mesenchymal stem cells (BM- MSC)
2506/1361	. . . from dental pulp or dental follicle stem cells
2506/1369	. . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2506/1376	. . . from mesenchymal stem cells derived from hair follicles
2506/1384	. . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2506/1392	. . . from mesenchymal stem cells from other natural sources
2506/14	. from hepatocytes
2506/22	. from pancreatic cells
2506/23	. from cells of the gastro-intestinal tract
2506/24	. from cells of the genital tract, from non-germinal gonad cells
2506/243	. . from cells of the female genital tract cells, from non-germinal ovarian cells
2506/246	. . from cells of the male genital tract cells, from non-germinal testis cells
2506/25	. from renal cells, from cells of the urinary tract

- 2506/27 . from lung cells, from cells of the respiratory tract
- 2506/28 . from vascular endothelial cells
- 2506/30 . from cancer cells, e.g. reversion of tumour cells

NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

- 2506/45 . from artificially induced pluripotent stem cells
- 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes**
- 2509/10 . Mechanical dissociation
- 2510/00 Genetically modified cells**
- 2510/02 . Cells for production
- 2510/04 . Immortalised cells
- 2511/00 Cells for large scale production**
- 2513/00 3D culture**
- 2517/00 Cells related to new breeds of animals**
- 2517/02 . Cells from transgenic animals
- 2517/04 . Cells produced using nuclear transfer
- 2517/10 . Conditioning of cells for *in vitro* fecondation or nuclear transfer
- 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces**
- 2521/10 . Sound, e.g. ultrasounds
- 2523/00 Culture process characterised by temperature**
- 2525/00 Culture process characterised by gravity, e.g. microgravity**
- 2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration**
- 2529/00 Culture process characterised by the use of electromagnetic stimulation**
- 2529/10 . Stimulation by light
- 2531/00 Microcarriers**
- 2533/00 Supports or coatings for cell culture, characterised by material**
- 2533/10 . Mineral substrates
- 2533/12 . . Glass
- 2533/14 . . Ceramic
- 2533/18 . . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- 2533/20 . Small organic molecules
- 2533/30 . Synthetic polymers ([thermoreactive polymers, e.g. PNIPAm, C12N 2539/10](#))
- 2533/32 . . Polylysine, polyornithine
- 2533/40 . . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- 2533/50 . Proteins
- 2533/52 . . Fibronectin; Laminin
- 2533/54 . . Collagen; Gelatin
- 2533/56 . . Fibrin; Thrombin
- 2533/70 . Polysaccharides
- 2533/72 . . Chitin, chitosan
- 2533/74 . . Alginate
- 2533/76 . . Agarose, agar-agar

- 2533/78 . . Cellulose
- 2533/80 . . Hyaluronan
- 2533/90 . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- 2533/92 . . Amnion; Decellularised dermis or mucosa
- 2535/00 Supports or coatings for cell culture characterised by topography**
- 2535/10 . Patterned coating
- 2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment**
- 2537/10 . Cross-linking
- 2539/00 Supports and/or coatings for cell culture characterised by properties**
- 2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating
- 2700/00 Viruses**
- 2710/00 dsDNA Viruses ([not used](#))**
- 2710/00011 . dsDNA Viruses
- 2710/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/00023 . . Virus like particles [VLP]
- 2710/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . Special targeting system for viral vectors
- 2710/00051 . . Methods of production or purification of viral material
- 2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . Methods of inactivation or attenuation
- 2710/00062 . . . by genetic engineering
- 2710/00063 . . . by chemical treatment
- 2710/00064 . . . by serial passage
- 2710/00071 . . Demonstrated *in vivo* effect
- 2710/00088 . . For redistribution
- 2710/10011 . . Adenoviridae
- 2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . Virus like particles [VLP]

2710/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10162	by genetic engineering
2710/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10163	by chemical treatment
2710/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10164	by serial passage
2710/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10171	Demonstrated <u>in vivo</u> effect
2710/10041	. . .	Use of virus, viral particle or viral elements as a vector	2710/10188	For redistribution
2710/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/10211	Aviadenovirus, e.g. fowl adenovirus A
2710/10043	viral genome or elements thereof as genetic vector	2710/10221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/10222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10045	Special targeting system for viral vectors	2710/10223	Virus like particles [VLP]
2710/10051	. . .	Methods of production or purification of viral material	2710/10231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10061	. . .	Methods of inactivation or attenuation	2710/10233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10062	by genetic engineering	2710/10234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10063	by chemical treatment	2710/10241	Use of virus, viral particle or viral elements as a vector
2710/10064	by serial passage	2710/10242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10071	. . .	Demonstrated <u>in vivo</u> effect	2710/10243	viral genome or elements thereof as genetic vector
2710/10088	. . .	For redistribution	2710/10244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10111	. . .	Atadenovirus, e.g. ovine adenovirus D	2710/10245	Special targeting system for viral vectors
2710/10121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/10251	Methods of production or purification of viral material
2710/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/10252	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10123	Virus like particles [VLP]	2710/10261	Methods of inactivation or attenuation
2710/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10262	by genetic engineering
2710/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10263	by chemical treatment
2710/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10264	by serial passage
2710/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10271	Demonstrated <u>in vivo</u> effect
2710/10141	Use of virus, viral particle or viral elements as a vector	2710/10288	For redistribution
2710/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/10311	Mastadenovirus, e.g. human or simian adenoviruses
2710/10143	viral genome or elements thereof as genetic vector	2710/10321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/10322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10145	Special targeting system for viral vectors	2710/10323	Virus like particles [VLP]
2710/10151	Methods of production or purification of viral material	2710/10331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10152	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10161	Methods of inactivation or attenuation	2710/10333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2710/10334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
			2710/10341	Use of virus, viral particle or viral elements as a vector

2710/10342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10343	viral genome or elements thereof as genetic vector	2710/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10345	Special targeting system for viral vectors	2710/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10351	Methods of production or purification of viral material	2710/14041	. . .	Use of virus, viral particle or viral elements as a vector
2710/10352	relating to complementing cells and packaging systems for producing virus or viral particles	2710/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10361	Methods of inactivation or attenuation	2710/14043	viral genome or elements thereof as genetic vectore
2710/10362	by genetic engineering	2710/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10363	by chemical treatment	2710/14045	Special targeting system for viral vectors
2710/10364	by serial passage	2710/14051	. . .	Methods of production or purification of viral material
2710/10371	Demonstrated <u>in vivo</u> effect	2710/14052	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10388	For redistribution	2710/14061	. . .	Methods of inactivation or attenuation
2710/12011	. .	Asfarviridae	2710/14062	by genetic engineering
2710/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/14063	by chemical treatment
2710/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/14064	by serial passage
2710/12023	. . .	Virus like particles [VLP]	2710/14071	. . .	Demonstrated <u>in vivo</u> effect
2710/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/14088	. . .	For redistribution
2710/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/14111	. . .	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
2710/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/12041	. . .	Use of virus, viral particle or viral elements as a vector	2710/14123	Virus like particles [VLP]
2710/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/12043	viral genome or elements thereof as genetic vector	2710/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/12045	Special targeting system for viral vectors	2710/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/12051	. . .	Methods of production or purification of viral material	2710/14141	Use of virus, viral particle or viral elements as a vector
2710/12052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/12061	. . .	Methods of inactivation or attenuation	2710/14143	viral genome or elements thereof as genetic vector
2710/12062	by genetic engineering	2710/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/12063	by chemical treatment	2710/14145	Special targeting system for viral vectors
2710/12064	by serial passage	2710/14151	Methods of production or purification of viral material
2710/12071	. . .	Demonstrated <u>in vivo</u> effect	2710/14152	relating to complementing cells and packaging systems for producing virus or viral particles
2710/12088	. . .	For redistribution			
2710/14011	. .	Baculoviridae			
2710/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2710/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2710/14023	. . .	Virus like particles [VLP]			

- 2710/14161 Methods of inactivation or attenuation
 2710/14162 by genetic engineering
 2710/14163 by chemical treatment
 2710/14164 by serial passage
 2710/14171 Demonstrated in vivo effect
 2710/14188 For redistribution
 2710/16011 . . Herpesviridae
 2710/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/16023 . . . Virus like particles [VLP]
 2710/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
 2710/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
 2710/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
 2710/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
 2710/16041 . . . Use of virus, viral particle or viral elements as a vector
 2710/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
 2710/16043 viral genome or elements thereof as genetic vector
 2710/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
 2710/16045 Special targeting system for viral vectors
 2710/16051 . . . Methods of production or purification of viral material
 2710/16052 relating to complementing cells and packaging systems for producing virus or viral particles
 2710/16061 . . . Methods of inactivation or attenuation
 2710/16062 by genetic engineering
 2710/16063 by chemical treatment
 2710/16064 by serial passage
 2710/16071 . . . Demonstrated in vivo effect
 2710/16088 . . . For redistribution
 2710/16111 . . . Cytomegalovirus, e.g. human herpesvirus 5
 2710/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/16123 Virus like particles [VLP]
 2710/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
 2710/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
 2710/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
 2710/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
 2710/16141 Use of virus, viral particle or viral elements as a vector
 2710/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
 2710/16143 viral genome or elements thereof as genetic vector
 2710/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
 2710/16145 Special targeting system for viral vectors
 2710/16151 Methods of production or purification of viral material
 2710/16152 relating to complementing cells and packaging systems for producing virus or viral particles
 2710/16161 Methods of inactivation or attenuation
 2710/16162 by genetic engineering
 2710/16163 by chemical treatment
 2710/16164 by serial passage
 2710/16171 Demonstrated in vivo effect
 2710/16188 For redistribution
 2710/16211 . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
 2710/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/16223 Virus like particles [VLP]
 2710/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
 2710/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
 2710/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
 2710/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
 2710/16241 Use of virus, viral particle or viral elements as a vector
 2710/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
 2710/16243 viral genome or elements thereof as genetic vector
 2710/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
 2710/16245 Special targeting system for viral vectors
 2710/16251 Methods of production or purification of viral material
 2710/16252 relating to complementing cells and packaging systems for producing virus or viral particles
 2710/16261 Methods of inactivation or attenuation
 2710/16262 by genetic engineering
 2710/16263 by chemical treatment
 2710/16264 by serial passage
 2710/16271 Demonstrated in vivo effect
 2710/16288 For redistribution
 2710/16311 Marek's disease virus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
 2710/16321 Viruses as such, e.g. new isolates, mutants or their genomic sequences

- 2710/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16323 Virus like particles [VLP]
- 2710/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16341 Use of virus, viral particle or viral elements as a vector
- 2710/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16343 viral genome or elements thereof as genetic vector
- 2710/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16345 Special targeting system for viral vectors
- 2710/16351 Methods of production or purification of viral material
- 2710/16352 relating to complementin g cells and packaging systems for producing virus or viral particles
- 2710/16361 Methods of inactivation or attenuation
- 2710/16362 by genetic engineering
- 2710/16363 by chemical treatment
- 2710/16364 by serial passage
- 2710/16371 Demonstrated in vivo effect
- 2710/16388 For redistribution
- 2710/16411 . . . Rhadinovirus, e.g. human herpesvirus 8
- 2710/16421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16423 Virus like particles [VLP]
- 2710/16431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16441 Use of virus, viral particle or viral elements as a vector
- 2710/16442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16443 viral genome or elements thereof as genetic vector
- 2710/16444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16445 Special targeting system for viral vectors
- 2710/16451 Methods of production or purification of viral material
- 2710/16452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16461 Methods of inactivation or attenuation
- 2710/16462 by genetic engineering
- 2710/16463 by chemical treatment
- 2710/16464 by serial passage
- 2710/16471 Demonstrated in vivo effect
- 2710/16488 For redistribution
- 2710/16511 . . . Roseolovirus, e.g. human herpesvirus 6, 7
- 2710/16521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16523 Virus like particles [VLP]
- 2710/16531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
- 2710/16541 Use of virus, viral particle or viral elements as a vector
- 2710/16542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16543 viral genome or elements thereof as genetic vector
- 2710/16544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16545 Special targeting system for viral vectors
- 2710/16551 Methods of production or purification of viral material
- 2710/16552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16561 Methods of inactivation or attenuation
- 2710/16562 by genetic engineering
- 2710/16563 by chemical treatment
- 2710/16564 by serial passage
- 2710/16571 Demonstrated in vivo effect
- 2710/16588 For redistribution
- 2710/16611 . . . Simplexvirus, e.g. human herpesvirus 1, 2
- 2710/16621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16623 Virus like particles [VLP]
- 2710/16631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- 2710/16641 Use of virus, viral particle or viral elements as a vector
- 2710/16642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16643 viral genome or elements thereof as genetic vector
- 2710/16644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16645 Special targeting system for viral vectors
- 2710/16651 Methods of production or purification of viral material
- 2710/16652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16661 Methods of inactivation or attenuation
- 2710/16662 by genetic engineering
- 2710/16663 by chemical treatment
- 2710/16664 by serial passage
- 2710/16671 Demonstrated in vivo effect
- 2710/16688 For redistribution
- 2710/16711 Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- 2710/16721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16723 Virus like particles [VLP]
- 2710/16731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16741 Use of virus, viral particle or viral elements as a vector
- 2710/16742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16743 viral genome or elements thereof as genetic vector
- 2710/16744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16745 Special targeting system for viral vectors
- 2710/16751 Methods of production or purification of viral material
- 2710/16752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16761 Methods of inactivation or attenuation
- 2710/16762 by genetic engineering
- 2710/16763 by chemical treatment
- 2710/16764 by serial passage
- 2710/16771 Demonstrated in vivo effect
- 2710/16788 For redistribution
- 2710/18011 Nimaviridae
- 2710/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/18023 Virus like particles [VLP]
- 2710/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/18041 Use of virus, viral particle or viral elements as a vector
- 2710/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/18043 viral genome or elements thereof as genetic vector
- 2710/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/18045 Special targeting system for viral vectors
- 2710/18051 Methods of production or purification of viral material
- 2710/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/18061 Methods of inactivation or attenuation
- 2710/18062 by genetic engineering
- 2710/18063 by chemical treatment
- 2710/18064 by serial passage
- 2710/18071 Demonstrated in vivo effect
- 2710/18088 For redistribution
- 2710/20011 Papillomaviridae
- 2710/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/20023 Virus like particles [VLP]
- 2710/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/20041 Use of virus, viral particle or viral elements as a vector
- 2710/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/20043 viral genome or elements thereof as genetic vector
- 2710/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/20045 Special targeting system for viral vectors
- 2710/20051 Methods of production or purification of viral material

- 2710/20052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/20061 . . . Methods of inactivation or attenuation
- 2710/20062 . . . by genetic engineering
- 2710/20063 . . . by chemical treatment
- 2710/20064 . . . by serial passage
- 2710/20071 . . . Demonstrated in vivo effect
- 2710/20088 . . . For redistribution
- 2710/22011 . . . Polyomaviridae, e.g. polyoma, SV40, JC
- 2710/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/22023 . . . Virus like particles [VLP]
- 2710/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/22042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/22043 . . . viral genome or elements thereof as genetic vector
- 2710/22044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/22045 . . . Special targeting system for viral vectors
- 2710/22051 . . . Methods of production or purification of viral material
- 2710/22052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/22061 . . . Methods of inactivation or attenuation
- 2710/22062 . . . by genetic engineering
- 2710/22063 . . . by chemical treatment
- 2710/22064 . . . by serial passage
- 2710/22071 . . . Demonstrated in vivo effect
- 2710/22088 . . . For redistribution
- 2710/24011 . . . Poxviridae
- 2710/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24023 . . . Virus like particles [VLP]
- 2710/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/24042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24043 . . . viral genome or elements thereof as genetic vector
- 2710/24044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24045 . . . Special targeting system for viral vectors
- 2710/24051 . . . Methods of production or purification of viral material
- 2710/24052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24061 . . . Methods of inactivation or attenuation
- 2710/24062 . . . by genetic engineering
- 2710/24063 . . . by chemical treatment
- 2710/24064 . . . by serial passage
- 2710/24071 . . . Demonstrated in vivo effect
- 2710/24088 . . . For redistribution
- 2710/24111 . . . Orthopoxvirus, e.g. vaccinia virus, variola
- 2710/24121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24123 . . . Virus like particles [VLP]
- 2710/24131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24141 . . . Use of virus, viral particle or viral elements as a vector
- 2710/24142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24143 . . . viral genome or elements thereof as genetic vector
- 2710/24144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24145 . . . Special targeting system for viral vectors
- 2710/24151 . . . Methods of production or purification of viral material
- 2710/24152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24161 . . . Methods of inactivation or attenuation
- 2710/24162 . . . by genetic engineering
- 2710/24163 . . . by chemical treatment
- 2710/24164 . . . by serial passage
- 2710/24171 . . . Demonstrated in vivo effect
- 2710/24188 . . . For redistribution
- 2710/24211 . . . Parapoxvirus, e.g. Orf virus
- 2710/24221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

- 2710/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24223 Virus like particles [VLP]
- 2710/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24241 Use of virus, viral particle or viral elements as a vector
- 2710/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24243 viral genome or elements thereof as genetic vector
- 2710/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24245 Special targeting system for viral vectors
- 2710/24251 Methods of production or purification of viral material
- 2710/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24261 Methods of inactivation or attenuation
- 2710/24262 by genetic engineering
- 2710/24263 by chemical treatment
- 2710/24264 by serial passage
- 2710/24271 Demonstrated in vivo effect
- 2710/24288 For redistribution
- 2720/00** **dsRNA Viruses (not used)**
- 2720/00011 . dsRNA Viruses
- 2720/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023 . . Virus like particles [VLP]
- 2720/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . Special targeting system for viral vectors
- 2720/00051 . . Methods of production or purification of viral material
- 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . Methods of inactivation or attenuation
- 2720/00062 . . . by genetic engineering
- 2720/00063 . . . by chemical treatment
- 2720/00064 . . . by serial passage
- 2720/00071 . . Demonstrated in vivo effect
- 2720/00088 . . For redistribution
- 2720/10011 . . Birnaviridae
- 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . Virus like particles [VLP]
- 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/10043 viral genome or elements thereof as genetic vector
- 2720/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/10045 Special targeting system for viral vectors
- 2720/10051 . . . Methods of production or purification of viral material
- 2720/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/10061 . . . Methods of inactivation or attenuation
- 2720/10062 by genetic engineering
- 2720/10063 by chemical treatment
- 2720/10064 by serial passage
- 2720/10071 . . . Demonstrated in vivo effect
- 2720/10088 . . . For redistribution
- 2720/12011 . . Reoviridae
- 2720/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12023 . . . Virus like particles [VLP]
- 2720/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2720/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12043 viral genome or elements thereof as genetic vector
- 2720/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12045 Special targeting system for viral vectors
- 2720/12051 . . . Methods of production or purification of viral material
- 2720/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12061 . . . Methods of inactivation or attenuation
- 2720/12062 by genetic engineering
- 2720/12063 by chemical treatment
- 2720/12064 by serial passage
- 2720/12071 . . . Demonstrated in vivo effect
- 2720/12088 . . . For redistribution
- 2720/12111 . . . Orbivirus, e.g. bluetongue virus
- 2720/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12123 Virus like particles [VLP]
- 2720/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12141 Use of virus, viral particle or viral elements as a vector
- 2720/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12143 viral genome or elements thereof as genetic vector
- 2720/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12145 Special targeting system for viral vectors
- 2720/12151 Methods of production or purification of viral material
- 2720/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12161 Methods of inactivation or attenuation
- 2720/12162 by genetic engineering
- 2720/12163 by chemical treatment
- 2720/12164 by serial passage
- 2720/12171 Demonstrated in vivo effect
- 2720/12188 For redistribution
- 2720/12211 . . . Orthoreovirus, e.g. mammalian orthoreovirus
- 2720/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12223 Virus like particles [VLP]
- 2720/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12241 Use of virus, viral particle or viral elements as a vector
- 2720/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12243 viral genome or elements thereof as genetic vector
- 2720/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12245 Special targeting system for viral vectors
- 2720/12251 Methods of production or purification of viral material
- 2720/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12261 Methods of inactivation or attenuation
- 2720/12262 by genetic engineering
- 2720/12263 by chemical treatment
- 2720/12264 by serial passage
- 2720/12271 Demonstrated in vivo effect
- 2720/12288 For redistribution
- 2720/12311 . . . Rotavirus, e.g. rotavirus A
- 2720/12321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 Virus like particles [VLP]
- 2720/12331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 Use of virus, viral particle or viral elements as a vector
- 2720/12342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 viral genome or elements thereof as genetic vector
- 2720/12344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 Special targeting system for viral vectors

2720/12351 Methods of production or purification of viral material	2730/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12352 relating to complementing cells and packaging systems for producing virus or viral particles	2730/10041 Use of virus, viral particle or viral elements as a vector
2720/12361 Methods of inactivation or attenuation	2730/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12362 by genetic engineering	2730/10043 viral genome or elements thereof as genetic vector
2720/12363 by chemical treatment	2730/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12364 by serial passage	2730/10045 Special targeting system for viral vectors
2720/12371 Demonstrated <u>in vivo</u> effect	2730/10051 Methods of production or purification of viral material
2720/12388 For redistribution	2730/10052 relating to complementing cells and packaging systems for producing virus or viral particles
2730/00	Reverse Transcribing DNA Viruses (not used)	2730/10061 Methods of inactivation or attenuation
2730/00011	. Reverse Transcribing DNA Viruses	2730/10062 by genetic engineering
2730/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences	2730/10063 by chemical treatment
2730/00022	. . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2730/10064 by serial passage
2730/00023	. . Virus like particles [VLP]	2730/10071 Demonstrated <u>in vivo</u> effect
2730/00031	. . Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2730/10088 For redistribution
2730/00032	. . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2730/10111 Orthohepadnavirus, e.g. hepatitis B virus
2730/00033	. . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2730/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/00034	. . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/00041	. . Use of virus, viral particle or viral elements as a vector	2730/10123 Virus like particles [VLP]
2730/00042	. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2730/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2730/00043	. . . viral genome or elements thereof as genetic vector	2730/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2730/00044	. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2730/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2730/00045	. . . Special targeting system for viral vectors	2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2730/00051	. . Methods of production or purification of viral material	2730/10141 Use of virus, viral particle or viral elements as a vector
2730/00052	. . . relating to complementing cells and packaging systems for producing virus or viral particles	2730/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2730/00061	. . Methods of inactivation or attenuation	2730/10143 viral genome or elements thereof as genetic vector
2730/00062	. . . by genetic engineering	2730/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/00063	. . . by chemical treatment	2730/10145 Special targeting system for viral vectors
2730/00064	. . . by serial passage	2730/10151 Methods of production or purification of viral material
2730/00071	. . Demonstrated <u>in vivo</u> effect	2730/10152 relating to complementing cells and packaging systems for producing virus or viral particles
2730/00088	. . For redistribution	2730/10161 Methods of inactivation or attenuation
2730/10011	. . Hepadnaviridae	2730/10162 by genetic engineering
2730/10021	. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences	2730/10163 by chemical treatment
2730/10022	. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2730/10164 by serial passage
2730/10023	. . . Virus like particles [VLP]	2730/10171 Demonstrated <u>in vivo</u> effect
2730/10031	. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2730/10188 For redistribution
2730/10032	. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/00	Reverse Transcribing RNA Viruses (not used)
2730/10033	. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory		

- 2740/00011 . Reverse Transcribing RNA Viruses
- 2740/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 . . Virus like particles [VLP]
- 2740/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 . . Use of virus, viral particle or viral elements as a vector
- 2740/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 . . . viral genome or elements thereof as genetic vector
- 2740/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/00045 . . . Special targeting system for viral vectors
- 2740/00051 . . Methods of production or purification of viral material
- 2740/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/00061 . . Methods of inactivation or attenuation
- 2740/00062 . . . by genetic engineering
- 2740/00063 . . . by chemical treatment
- 2740/00064 . . . by serial passage
- 2740/00071 . . Demonstrated in vivo effect
- 2740/00088 . . For redistribution
- 2740/10011 . . Retroviridae
- 2740/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/10023 . . . Virus like particles [VLP]
- 2740/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/10043 viral genome or elements thereof as genetic vector
- 2740/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/10045 Special targeting system for viral vectors
- 2740/10051 . . . Methods of production or purification of viral material
- 2740/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/10061 . . . Methods of inactivation or attenuation
- 2740/10062 by genetic engineering
- 2740/10063 by chemical treatment
- 2740/10064 by serial passage
- 2740/10071 . . . Demonstrated in vivo effect
- 2740/10088 . . . For redistribution
- 2740/11011 . . . Alpharetrovirus, e.g. avian leucosis virus
- 2740/11021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/11022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/11023 Virus like particles [VLP]
- 2740/11031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/11032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/11033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/11034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/11041 Use of virus, viral particle or viral elements as a vector
- 2740/11042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/11043 viral genome or elements thereof as genetic vector
- 2740/11044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/11045 Special targeting system for viral vectors
- 2740/11051 Methods of production or purification of viral material
- 2740/11052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/11061 Methods of inactivation or attenuation
- 2740/11062 by genetic engineering
- 2740/11063 by chemical treatment
- 2740/11064 by serial passage
- 2740/11071 Demonstrated in vivo effect
- 2740/11088 For redistribution
- 2740/12011 . . . Betaretrovirus, e.g. mouse mammary tumour virus
- 2740/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/12023 Virus like particles [VLP]
- 2740/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2740/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/12041 Use of virus, viral particle or viral elements as a vector
- 2740/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/12043 viral genome or elements thereof as genetic vector
- 2740/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/12045 Special targeting system for viral vectors
- 2740/12051 Methods of production or purification of viral material
- 2740/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/12061 Methods of inactivation or attenuation
- 2740/12062 by genetic engineering
- 2740/12063 by chemical treatment
- 2740/12064 by serial passage
- 2740/12071 Demonstrated in vivo effect
- 2740/12088 For redistribution
- 2740/13011 Gammaretrovirus, e.g. murine leukaemia virus
- 2740/13021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/13022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/13023 Virus like particles [VLP]
- 2740/13031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/13032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/13033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/13034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/13041 Use of virus, viral particle or viral elements as a vector
- 2740/13042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/13043 viral genome or elements thereof as genetic vector
- 2740/13044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/13045 Special targeting system for viral vectors
- 2740/13051 Methods of production or purification of viral material
- 2740/13052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/13061 Methods of inactivation or attenuation
- 2740/13062 by genetic engineering
- 2740/13063 by chemical treatment
- 2740/13064 by serial passage
- 2740/13071 Demonstrated in vivo effect
- 2740/13088 For redistribution
- 2740/14011 Deltaretrovirus, e.g. bovine leukaemia virus
- 2740/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/14023 Virus like particles [VLP]
- 2740/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/14041 Use of virus, viral particle or viral elements as a vector
- 2740/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/14043 viral genome or elements thereof as genetic vector
- 2740/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/14045 Special targeting system for viral vectors
- 2740/14051 Methods of production or purification of viral material
- 2740/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/14061 Methods of inactivation or attenuation
- 2740/14062 by genetic engineering
- 2740/14063 by chemical treatment
- 2740/14064 by serial passage
- 2740/14071 Demonstrated in vivo effect
- 2740/14088 For redistribution
- 2740/15011 Lentivirus, not HIV, e.g. FIV, SIV
- 2740/15021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/15022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/15023 Virus like particles [VLP]
- 2740/15031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/15032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/15033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/15034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/15041 Use of virus, viral particle or viral elements as a vector
- 2740/15042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/15043 viral genome or elements thereof as genetic vector
- 2740/15044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/15045 Special targeting system for viral vectors

2740/15051	Methods of production or purification of viral material	2740/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/15052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/16271	Demonstrated <u>in vivo</u> effect
2740/15061	Methods of inactivation or attenuation	2740/16288	For redistribution
2740/15062	by genetic engineering	2740/16311	concerning HIV regulatory proteins
2740/15063	by chemical treatment	2740/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/15064	by serial passage	2740/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/15071	Demonstrated <u>in vivo</u> effect	2740/16371	Demonstrated <u>in vivo</u> effect
2740/15088	For redistribution	2740/16388	For redistribution
2740/16011	Human Immunodeficiency Virus, HIV	2740/17011	Spumavirus, e.g. chimpanzee foamy virus
2740/16021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/17021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/16022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/17022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16023	Virus like particles [VLP]	2740/17023	Virus like particles [VLP]
2740/16031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/17031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/16032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/17032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/16033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/17033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/16034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/17034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16041	Use of virus, viral particle or viral elements as a vector	2740/17041	Use of virus, viral particle or viral elements as a vector
2740/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/17042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/16043	viral genome or elements thereof as genetic vector	2740/17043	viral genome or elements thereof as genetic vector
2740/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/17044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/16045	Special targeting system for viral vectors	2740/17045	Special targeting system for viral vectors
2740/16051	Methods of production or purification of viral material	2740/17051	Methods of production or purification of viral material
2740/16052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/17052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/16061	Methods of inactivation or attenuation	2740/17061	Methods of inactivation or attenuation
2740/16062	by genetic engineering	2740/17062	by genetic engineering
2740/16063	by chemical treatment	2740/17063	by chemical treatment
2740/16064	by serial passage	2740/17064	by serial passage
2740/16071	Demonstrated <u>in vivo</u> effect	2740/17071	Demonstrated <u>in vivo</u> effect
2740/16088	For redistribution	2740/17088	For redistribution
2740/16111	concerning HIV env			
2740/16122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2740/16134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein			
2740/16171	Demonstrated <u>in vivo</u> effect			
2740/16188	For redistribution			
2740/16211	concerning HIV gagpol			
2740/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
			2750/00		ssDNA Viruses (not used)
			2750/00011	ssDNA Viruses
			2750/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
			2750/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2750/00023	Virus like particles [VLP]
			2750/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2750/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/00041 . . Use of virus, viral particle or viral elements as a vector
- 2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/00043 . . . viral genome or elements thereof as genetic vector
- 2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/00045 . . . Special targeting system for viral vectors
- 2750/00051 . . Methods of production or purification of viral material
- 2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/00061 . . Methods of inactivation or attenuation
- 2750/00062 . . . by genetic engineering
- 2750/00063 . . . by chemical treatment
- 2750/00064 . . . by serial passage
- 2750/00071 . . Demonstrated in vivo effect
- 2750/00088 . . For redistribution
- 2750/10011 . . Circoviridae
- 2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . Virus like particles [VLP]
- 2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 viral genome or elements thereof as genetic vector
- 2750/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 Special targeting system for viral vectors
- 2750/10051 . . . Methods of production or purification of viral material
- 2750/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . Methods of inactivation or attenuation
- 2750/10062 by genetic engineering
- 2750/10063 by chemical treatment
- 2750/10064 by serial passage
- 2750/10071 . . . Demonstrated in vivo effect
- 2750/10088 . . . For redistribution
- 2750/12011 . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 viral genome or elements thereof as genetic vector
- 2750/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 Special targeting system for viral vectors
- 2750/12051 . . . Methods of production or purification of viral material
- 2750/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 by genetic engineering
- 2750/12063 by chemical treatment
- 2750/12064 by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . For redistribution
- 2750/14011 . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 viral genome or elements thereof as genetic vector

- 2750/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 Special targeting system for viral vectors
- 2750/14051 Methods of production or purification of viral material
- 2750/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 Methods of inactivation or attenuation
- 2750/14062 by genetic engineering
- 2750/14063 by chemical treatment
- 2750/14064 by serial passage
- 2750/14071 Demonstrated in vivo effect
- 2750/14088 For redistribution
- 2750/14111 Dependovirus, e.g. adenoassociated viruses
- 2750/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 Virus like particles [VLP]
- 2750/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 Use of virus, viral particle or viral elements as a vector
- 2750/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 viral genome or elements thereof as genetic vector
- 2750/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 Special targeting system for viral vectors
- 2750/14151 Methods of production or purification of viral material
- 2750/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 Methods of inactivation or attenuation
- 2750/14162 by genetic engineering
- 2750/14163 by chemical treatment
- 2750/14164 by serial passage
- 2750/14171 Demonstrated in vivo effect
- 2750/14188 For redistribution
- 2750/14211 Erythrovirus, e.g. B19 virus
- 2750/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 Virus like particles [VLP]
- 2750/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 Use of virus, viral particle or viral elements as a vector
- 2750/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 viral genome or elements thereof as genetic vector
- 2750/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 Special targeting system for viral vectors
- 2750/14251 Methods of production or purification of viral material
- 2750/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 Methods of inactivation or attenuation
- 2750/14262 by genetic engineering
- 2750/14263 by chemical treatment
- 2750/14264 by serial passage
- 2750/14271 Demonstrated in vivo effect
- 2750/14288 For redistribution
- 2750/14311 Parvovirus, e.g. minute virus of mice
- 2750/14321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 Virus like particles [VLP]
- 2750/14331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 Use of virus, viral particle or viral elements as a vector
- 2750/14342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 viral genome or elements thereof as genetic vector
- 2750/14344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 Special targeting system for viral vectors
- 2750/14351 Methods of production or purification of viral material
- 2750/14352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 Methods of inactivation or attenuation
- 2750/14362 by genetic engineering
- 2750/14363 by chemical treatment
- 2750/14364 by serial passage
- 2750/14371 Demonstrated in vivo effect

- 2750/14388 For redistribution
- 2760/00 ssRNA Viruses negative-sense (not used)**
- 2760/00011 . ssRNA Viruses negative-sense
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . Special targeting system for viral vectors
- 2760/00051 . . Methods of production or purification of viral material
- 2760/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . Methods of inactivation or attenuation
- 2760/00062 . . . by genetic engineering
- 2760/00063 . . . by chemical treatment
- 2760/00064 . . . by serial passage
- 2760/00071 . . Demonstrated in vivo effect
- 2760/00088 . . For redistribution
- 2760/10011 . . Arenaviridae
- 2760/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . Virus like particles [VLP]
- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 viral genome or elements thereof as genetic vector
- 2760/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 Special targeting system for viral vectors
- 2760/10051 Methods of production or purification of viral material
- 2760/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 Methods of inactivation or attenuation
- 2760/10062 by genetic engineering
- 2760/10063 by chemical treatment
- 2760/10064 by serial passage
- 2760/10071 Demonstrated in vivo effect
- 2760/10088 For redistribution
- 2760/10111 Deltavirus, e.g. hepatitis delta virus
- 2760/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 Virus like particles [VLP]
- 2760/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10141 Use of virus, viral particle or viral elements as a vector
- 2760/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10143 viral genome or elements thereof as genetic vector
- 2760/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10145 Special targeting system for viral vectors
- 2760/10151 Methods of production or purification of viral material
- 2760/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10161 Methods of inactivation or attenuation
- 2760/10162 by genetic engineering
- 2760/10163 by chemical treatment
- 2760/10164 by serial passage
- 2760/10171 Demonstrated in vivo effect
- 2760/10188 For redistribution
- 2760/12011 . . Bunyaviridae
- 2760/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12023 . . . Virus like particles [VLP]
- 2760/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2760/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12043 viral genome or elements thereof as genetic vector
- 2760/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12045 Special targeting system for viral vectors
- 2760/12051 . . . Methods of production or purification of viral material
- 2760/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12061 . . . Methods of inactivation or attenuation
- 2760/12062 by genetic engineering
- 2760/12063 by chemical treatment
- 2760/12064 by serial passage
- 2760/12071 . . . Demonstrated in vivo effect
- 2760/12088 . . . For redistribution
- 2760/12111 . . . Hantavirus, e.g. Hantaan virus
- 2760/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 Virus like particles [VLP]
- 2760/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 Use of virus, viral particle or viral elements as a vector
- 2760/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12143 viral genome or elements thereof as genetic vector
- 2760/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12145 Special targeting system for viral vectors
- 2760/12151 Methods of production or purification of viral material
- 2760/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12161 Methods of inactivation or attenuation
- 2760/12162 by genetic engineering
- 2760/12163 by chemical treatment
- 2760/12164 by serial passage
- 2760/12171 Demonstrated in vivo effect
- 2760/12188 For redistribution
- 2760/12211 . . . Phlebovirus, e.g. Rift Valley fever virus
- 2760/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12223 Virus like particles [VLP]
- 2760/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12241 Use of virus, viral particle or viral elements as a vector
- 2760/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12243 viral genome or elements thereof as genetic vector
- 2760/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12245 Special targeting system for viral vectors
- 2760/12251 Methods of production or purification of viral material
- 2760/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 Methods of inactivation or attenuation
- 2760/12262 by genetic engineering
- 2760/12263 by chemical treatment
- 2760/12264 by serial passage
- 2760/12271 Demonstrated in vivo effect
- 2760/12288 For redistribution
- 2760/14011 . . Filoviridae
- 2760/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 . . . Virus like particles [VLP]
- 2760/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 viral genome or elements thereof as genetic vector

- 2760/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 Special targeting system for viral vectors
- 2760/14051 Methods of production or purification of viral material
- 2760/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 Methods of inactivation or attenuation
- 2760/14062 by genetic engineering
- 2760/14063 by chemical treatment
- 2760/14064 by serial passage
- 2760/14071 Demonstrated in vivo effect
- 2760/14088 For redistribution
- 2760/14111 Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 Virus like particles [VLP]
- 2760/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 Use of virus, viral particle or viral elements as a vector
- 2760/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 viral genome or elements thereof as genetic vector
- 2760/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 Special targeting system for viral vectors
- 2760/14151 Methods of production or purification of viral material
- 2760/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 Methods of inactivation or attenuation
- 2760/14162 by genetic engineering
- 2760/14163 by chemical treatment
- 2760/14164 by serial passage
- 2760/14171 Demonstrated in vivo effect
- 2760/14188 For redistribution
- 2760/14211 Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 Use of virus, viral particle or viral elements as a vector
- 2760/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 viral genome or elements thereof as genetic vector
- 2760/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 Special targeting system for viral vectors
- 2760/14251 Methods of production or purification of viral material
- 2760/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 Methods of inactivation or attenuation
- 2760/14262 by genetic engineering
- 2760/14263 by chemical treatment
- 2760/14264 by serial passage
- 2760/14271 Demonstrated in vivo effect
- 2760/14288 For redistribution
- 2760/16011 Orthomyxoviridae
- 2760/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 Virus like particles [VLP]
- 2760/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 Use of virus, viral particle or viral elements as a vector
- 2760/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 viral genome or elements thereof as genetic vector
- 2760/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 Special targeting system for viral vectors
- 2760/16051 Methods of production or purification of viral material
- 2760/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 Methods of inactivation or attenuation
- 2760/16062 by genetic engineering
- 2760/16063 by chemical treatment

- 2760/16064 by serial passage
- 2760/16071 . . . Demonstrated in vivo effect
- 2760/16088 . . . For redistribution
- 2760/16111 . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 Virus like particles [VLP]
- 2760/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 Use of virus, viral particle or viral elements as a vector
- 2760/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 viral genome or elements thereof as genetic vector
- 2760/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 Special targeting system for viral vectors
- 2760/16151 Methods of production or purification of viral material
- 2760/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 Methods of inactivation or attenuation
- 2760/16162 by genetic engineering
- 2760/16163 by chemical treatment
- 2760/16164 by serial passage
- 2760/16171 Demonstrated in vivo effect
- 2760/16188 For redistribution
- 2760/16211 . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 Virus like particles [VLP]
- 2760/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 Use of virus, viral particle or viral elements as a vector
- 2760/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 viral genome or elements thereof as genetic vector
- 2760/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 Special targeting system for viral vectors
- 2760/16251 Methods of production or purification of viral material
- 2760/16252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 Methods of inactivation or attenuation
- 2760/16262 by genetic engineering
- 2760/16263 by chemical treatment
- 2760/16264 by serial passage
- 2760/16271 Demonstrated in vivo effect
- 2760/16288 For redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 Virus like particles [VLP]
- 2760/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 Use of virus, viral particle or viral elements as a vector
- 2760/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 viral genome or elements thereof as genetic vector
- 2760/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 Special targeting system for viral vectors
- 2760/16351 Methods of production or purification of viral material
- 2760/16352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 Methods of inactivation or attenuation
- 2760/16362 by genetic engineering
- 2760/16363 by chemical treatment
- 2760/16364 by serial passage
- 2760/16371 Demonstrated in vivo effect
- 2760/16388 For redistribution
- 2760/18011 . . . Paramyxoviridae
- 2760/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 Virus like particles [VLP]
- 2760/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2760/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 viral genome or elements thereof as genetic vector
- 2760/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 Special targeting system for viral vectors
- 2760/18051 . . . Methods of production or purification of viral material
- 2760/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 . . . Methods of inactivation or attenuation
- 2760/18062 by genetic engineering
- 2760/18063 by chemical treatment
- 2760/18064 by serial passage
- 2760/18071 . . . Demonstrated in vivo effect
- 2760/18088 . . . For redistribution
- 2760/18111 . . . Avulavirus, e.g. Newcastle disease virus
- 2760/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 Virus like particles [VLP]
- 2760/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 Use of virus, viral particle or viral elements as a vector
- 2760/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 viral genome or elements thereof as genetic vector
- 2760/18144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18145 Special targeting system for viral vectors
- 2760/18151 Methods of production or purification of viral material
- 2760/18152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18161 Methods of inactivation or attenuation
- 2760/18162 by genetic engineering
- 2760/18163 by chemical treatment
- 2760/18164 by serial passage
- 2760/18171 Demonstrated in vivo effect
- 2760/18188 For redistribution
- 2760/18211 Henipavirus, e.g. hendra virus
- 2760/18221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 Virus like particles [VLP]
- 2760/18231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 Use of virus, viral particle or viral elements as a vector
- 2760/18242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 viral genome or elements thereof as genetic vector
- 2760/18244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 Special targeting system for viral vectors
- 2760/18251 Methods of production or purification of viral material
- 2760/18252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 Methods of inactivation or attenuation
- 2760/18262 by genetic engineering
- 2760/18263 by chemical treatment
- 2760/18264 by serial passage
- 2760/18271 Demonstrated in vivo effect
- 2760/18288 For redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 Virus like particles [VLP]
- 2760/18331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 Use of virus, viral particle or viral elements as a vector
- 2760/18342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 viral genome or elements thereof as genetic vector

- 2760/18344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 Special targeting system for viral vectors
- 2760/18351 Methods of production or purification of viral material
- 2760/18352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 Methods of inactivation or attenuation
- 2760/18362 by genetic engineering
- 2760/18363 by chemical treatment
- 2760/18364 by serial passage
- 2760/18371 Demonstrated in vivo effect
- 2760/18388 For redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 Virus like particles [VLP]
- 2760/18431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 Use of virus, viral particle or viral elements as a vector
- 2760/18442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 viral genome or elements thereof as genetic vector
- 2760/18444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 Special targeting system for viral vectors
- 2760/18451 Methods of production or purification of viral material
- 2760/18452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 Methods of inactivation or attenuation
- 2760/18462 by genetic engineering
- 2760/18463 by chemical treatment
- 2760/18464 by serial passage
- 2760/18471 Demonstrated in vivo effect
- 2760/18488 For redistribution
- 2760/18511 . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 Virus like particles [VLP]
- 2760/18531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 Use of virus, viral particle or viral elements as a vector
- 2760/18542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 viral genome or elements thereof as genetic vector
- 2760/18544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 Special targeting system for viral vectors
- 2760/18551 Methods of production or purification of viral material
- 2760/18552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 Methods of inactivation or attenuation
- 2760/18562 by genetic engineering
- 2760/18563 by chemical treatment
- 2760/18564 by serial passage
- 2760/18571 Demonstrated in vivo effect
- 2760/18588 For redistribution
- 2760/18611 . . . Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 Virus like particles [VLP]
- 2760/18631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 Use of virus, viral particle or viral elements as a vector
- 2760/18642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 viral genome or elements thereof as genetic vector
- 2760/18644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 Special targeting system for viral vectors
- 2760/18651 Methods of production or purification of viral material
- 2760/18652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 Methods of inactivation or attenuation
- 2760/18662 by genetic engineering

- 2760/18663 by chemical treatment
- 2760/18664 by serial passage
- 2760/18671 Demonstrated in vivo effect
- 2760/18688 For redistribution
- 2760/18711 Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 Virus like particles [VLP]
- 2760/18731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 Use of virus, viral particle or viral elements as a vector
- 2760/18742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 viral genome or elements thereof as genetic vector
- 2760/18744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 Special targeting system for viral vectors
- 2760/18751 Methods of production or purification of viral material
- 2760/18752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 Methods of inactivation or attenuation
- 2760/18762 by genetic engineering
- 2760/18763 by chemical treatment
- 2760/18764 by serial passage
- 2760/18771 Demonstrated in vivo effect
- 2760/18788 For redistribution
- 2760/18811 Sendai virus
- 2760/18821 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 Virus like particles [VLP]
- 2760/18831 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 Use of virus, viral particle or viral elements as a vector
- 2760/18842 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18843 viral genome or elements thereof as genetic vector
- 2760/18845 Special targeting system for viral vectors
- 2760/18851 Methods of production or purification of viral material
- 2760/18852 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18861 Methods of inactivation or attenuation
- 2760/18862 by genetic engineering
- 2760/18863 by chemical treatment
- 2760/18864 by serial passage
- 2760/18871 Demonstrated in vivo effect
- 2760/18888 For redistribution
- 2760/20011 Rhabdoviridae
- 2760/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20023 Virus like particles [VLP]
- 2760/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20041 Use of virus, viral particle or viral elements as a vector
- 2760/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20043 viral genome or elements thereof as genetic vector
- 2760/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20045 Special targeting system for viral vectors
- 2760/20051 Methods of production or purification of viral material
- 2760/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20061 Methods of inactivation or attenuation
- 2760/20062 by genetic engineering
- 2760/20063 by chemical treatment
- 2760/20064 by serial passage
- 2760/20071 Demonstrated in vivo effect
- 2760/20088 For redistribution
- 2760/20111 Lyssavirus, e.g. rabies virus
- 2760/20121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20123 Virus like particles [VLP]
- 2760/20131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2760/20133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20141	Use of virus, viral particle or viral elements as a vector
2760/20142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20143 viral genome or elements thereof as genetic vector
2760/20144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20145 Special targeting system for viral vectors
2760/20151	Methods of production or purification of viral material
2760/20152 relating to complementing cells and packaging systems for producing virus or viral particles
2760/20161	Methods of inactivation or attenuation
2760/20162 by genetic engineering
2760/20163 by chemical treatment
2760/20164 by serial passage
2760/20171	Demonstrated <u>in vivo</u> effect
2760/20188	For redistribution
2760/20211	Vesiculovirus, e.g. vesicular stomatitis Indiana virus
2760/20221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20223	Virus like particles [VLP]
2760/20231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20241	Use of virus, viral particle or viral elements as a vector
2760/20242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20243 viral genome or elements thereof as genetic vector
2760/20244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20245 Special targeting system for viral vectors
2760/20251	Methods of production or purification of viral material
2760/20252 relating to complementing cells and packaging systems for producing virus or viral particles
2760/20261	Methods of inactivation or attenuation
2760/20262 by genetic engineering
2760/20263 by chemical treatment
2760/20264 by serial passage
2760/20271	Demonstrated <u>in vivo</u> effect
2760/20288	For redistribution
2770/00		ssRNA Viruses positive-sense (not used)
2770/00011	ssRNA Viruses positive-sense
2770/00021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/00022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/00023 Virus like particles [VLP]
2770/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/00041 Use of virus, viral particle or viral elements as a vector
2770/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/00043 viral genome or elements thereof as genetic vector
2770/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/00045 Special targeting system for viral vectors
2770/00051 Methods of production or purification of viral material
2770/00052 relating to complementing cells and packaging systems for producing virus or viral particles
2770/00061	Methods of inactivation or attenuation
2770/00062 by genetic engineering
2770/00063 by chemical treatment
2770/00064 by serial passage
2770/00071	Demonstrated <u>in vivo</u> effect
2770/00088	For redistribution
2770/10011	Arteriviridae
2770/10021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/10022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/10023	Virus like particles [VLP]
2770/10031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/10032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/10033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/10034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/10041	Use of virus, viral particle or viral elements as a vector
2770/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/10043 viral genome or elements thereof as genetic vector

- 2770/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 Special targeting system for viral vectors
- 2770/10051 Methods of production or purification of viral material
- 2770/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 Methods of inactivation or attenuation
- 2770/10062 by genetic engineering
- 2770/10063 by chemical treatment
- 2770/10064 by serial passage
- 2770/10071 Demonstrated in vivo effect
- 2770/10088 For redistribution
- 2770/12011 Astroviridae
- 2770/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 Virus like particles [VLP]
- 2770/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 Use of virus, viral particle or viral elements as a vector
- 2770/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 viral genome or elements thereof as genetic vector
- 2770/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 Special targeting system for viral vectors
- 2770/12051 Methods of production or purification of viral material
- 2770/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 Methods of inactivation or attenuation
- 2770/12062 by genetic engineering
- 2770/12063 by chemical treatment
- 2770/12064 by serial passage
- 2770/12071 Demonstrated in vivo effect
- 2770/12088 For redistribution
- 2770/14011 Bromoviridae
- 2770/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 Virus like particles [VLP]
- 2770/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 Use of virus, viral particle or viral elements as a vector
- 2770/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 viral genome or elements thereof as genetic vector
- 2770/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 Special targeting system for viral vectors
- 2770/14051 Methods of production or purification of viral material
- 2770/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 Methods of inactivation or attenuation
- 2770/14062 by genetic engineering
- 2770/14063 by chemical treatment
- 2770/14064 by serial passage
- 2770/14071 Demonstrated in vivo effect
- 2770/14088 For redistribution
- 2770/16011 Caliciviridae
- 2770/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 Virus like particles [VLP]
- 2770/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 Use of virus, viral particle or viral elements as a vector
- 2770/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 viral genome or elements thereof as genetic vector
- 2770/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 Special targeting system for viral vectors
- 2770/16051 Methods of production or purification of viral material
- 2770/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 Methods of inactivation or attenuation
- 2770/16062 by genetic engineering
- 2770/16063 by chemical treatment
- 2770/16064 by serial passage
- 2770/16071 Demonstrated in vivo effect

- 2770/16088 . . . For redistribution
- 2770/18011 . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 viral genome or elements thereof as genetic vector
- 2770/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 Special targeting system for viral vectors
- 2770/18051 . . . Methods of production or purification of viral material
- 2770/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . Methods of inactivation or attenuation
- 2770/18062 by genetic engineering
- 2770/18063 by chemical treatment
- 2770/18064 by serial passage
- 2770/18071 . . . Demonstrated in vivo effect
- 2770/18088 . . . For redistribution
- 2770/20011 . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 viral genome or elements thereof as genetic vector
- 2770/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 Special targeting system for viral vectors
- 2770/20051 . . . Methods of production or purification of viral material
- 2770/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 . . . Methods of inactivation or attenuation
- 2770/20062 by genetic engineering
- 2770/20063 by chemical treatment
- 2770/20064 by serial passage
- 2770/20071 . . . Demonstrated in vivo effect
- 2770/20088 . . . For redistribution
- 2770/22011 . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 viral genome or elements thereof as genetic vector
- 2770/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 by genetic engineering
- 2770/22063 by chemical treatment
- 2770/22064 by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . For redistribution
- 2770/24011 . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 viral genome or elements thereof as genetic vector
- 2770/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 by genetic engineering
- 2770/24063 by chemical treatment
- 2770/24064 by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . For redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 Virus like particles [VLP]
- 2770/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 Use of virus, viral particle or viral elements as a vector
- 2770/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 viral genome or elements thereof as genetic vector
- 2770/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 Special targeting system for viral vectors
- 2770/24151 Methods of production or purification of viral material
- 2770/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 Methods of inactivation or attenuation
- 2770/24162 by genetic engineering
- 2770/24163 by chemical treatment
- 2770/24164 by serial passage
- 2770/24171 Demonstrated in vivo effect
- 2770/24188 For redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 Virus like particles [VLP]
- 2770/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 Use of virus, viral particle or viral elements as a vector
- 2770/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 viral genome or elements thereof as genetic vector
- 2770/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 Special targeting system for viral vectors
- 2770/24251 Methods of production or purification of viral material
- 2770/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 Methods of inactivation or attenuation
- 2770/24262 by genetic engineering
- 2770/24263 by chemical treatment
- 2770/24264 by serial passage
- 2770/24271 Demonstrated in vivo effect
- 2770/24288 For redistribution
- 2770/24311 . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 Virus like particles [VLP]
- 2770/24331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 Use of virus, viral particle or viral elements as a vector
- 2770/24342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 viral genome or elements thereof as genetic vector

- 2770/24344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 Special targeting system for viral vectors
- 2770/24351 Methods of production or purification of viral material
- 2770/24352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 Methods of inactivation or attenuation
- 2770/24362 by genetic engineering
- 2770/24363 by chemical treatment
- 2770/24364 by serial passage
- 2770/24371 Demonstrated in vivo effect
- 2770/24388 For redistribution
- 2770/26011 . . Flexiviridae
- 2770/26021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . Virus like particles [VLP]
- 2770/26031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 viral genome or elements thereof as genetic vector
- 2770/26044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 Special targeting system for viral vectors
- 2770/26051 . . . Methods of production or purification of viral material
- 2770/26052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . Methods of inactivation or attenuation
- 2770/26062 by genetic engineering
- 2770/26063 by chemical treatment
- 2770/26064 by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . For redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 viral genome or elements thereof as genetic vector
- 2770/28044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 by genetic engineering
- 2770/28063 by chemical treatment
- 2770/28064 by serial passage
- 2770/28071 . . . Demonstrated in vivo effect
- 2770/28088 . . . For redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 Virus like particles [VLP]
- 2770/28131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 Use of virus, viral particle or viral elements as a vector
- 2770/28142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 viral genome or elements thereof as genetic vector
- 2770/28144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 Special targeting system for viral vectors
- 2770/28151 Methods of production or purification of viral material
- 2770/28152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 Methods of inactivation or attenuation
- 2770/28162 by genetic engineering
- 2770/28163 by chemical treatment
- 2770/28164 by serial passage
- 2770/28171 Demonstrated in vivo effect

- 2770/28188 For redistribution
- 2770/30011 . . . Nodaviridae
- 2770/30021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 . . . Virus like particles [VLP]
- 2770/30031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/30042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 viral genome or elements thereof as genetic vector
- 2770/30044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 Special targeting system for viral vectors
- 2770/30051 . . . Methods of production or purification of viral material
- 2770/30052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 . . . Methods of inactivation or attenuation
- 2770/30062 by genetic engineering
- 2770/30063 by chemical treatment
- 2770/30064 by serial passage
- 2770/30071 . . . Demonstrated in vivo effect
- 2770/30088 . . . For redistribution
- 2770/32011 . . . Picornaviridae
- 2770/32021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 . . . Virus like particles [VLP]
- 2770/32031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/32042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 viral genome or elements thereof as genetic vector
- 2770/32044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 Special targeting system for viral vectors
- 2770/32051 . . . Methods of production or purification of viral material
- 2770/32052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 . . . Methods of inactivation or attenuation
- 2770/32062 by genetic engineering
- 2770/32063 by chemical treatment
- 2770/32064 by serial passage
- 2770/32071 . . . Demonstrated in vivo effect
- 2770/32088 . . . For redistribution
- 2770/32111 . . . Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 Virus like particles [VLP]
- 2770/32131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 Use of virus, viral particle or viral elements as a vector
- 2770/32142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 viral genome or elements thereof as genetic vector
- 2770/32144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 Special targeting system for viral vectors
- 2770/32151 Methods of production or purification of viral material
- 2770/32152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 Methods of inactivation or attenuation
- 2770/32162 by genetic engineering
- 2770/32163 by chemical treatment
- 2770/32164 by serial passage
- 2770/32171 Demonstrated in vivo effect
- 2770/32188 For redistribution
- 2770/32211 Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 Virus like particles [VLP]
- 2770/32231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/32233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 Use of virus, viral particle or viral elements as a vector
- 2770/32242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 viral genome or elements thereof as genetic vector
- 2770/32244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 Special targeting system for viral vectors
- 2770/32251 Methods of production or purification of viral material
- 2770/32252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 Methods of inactivation or attenuation
- 2770/32262 by genetic engineering
- 2770/32263 by chemical treatment
- 2770/32264 by serial passage
- 2770/32271 Demonstrated *in vivo* effect
- 2770/32288 For redistribution
- 2770/32311 Enterovirus
- 2770/32321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 Virus like particles [VLP]
- 2770/32331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 Use of virus, viral particle or viral elements as a vector
- 2770/32342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 viral genome or elements thereof as genetic vector
- 2770/32344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 Special targeting system for viral vectors
- 2770/32351 Methods of production or purification of viral material
- 2770/32352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 Methods of inactivation or attenuation
- 2770/32362 by genetic engineering
- 2770/32363 by chemical treatment
- 2770/32364 by serial passage
- 2770/32371 Demonstrated *in vivo* effect
- 2770/32388 For redistribution
- 2770/32411 Hepatovirus, i.e. hepatitis A virus
- 2770/32421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 Virus like particles [VLP]
- 2770/32431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 Use of virus, viral particle or viral elements as a vector
- 2770/32442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 viral genome or elements thereof as genetic vector
- 2770/32444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32445 Special targeting system for viral vectors
- 2770/32451 Methods of production or purification of viral material
- 2770/32452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32461 Methods of inactivation or attenuation
- 2770/32462 by genetic engineering
- 2770/32463 by chemical treatment
- 2770/32464 by serial passage
- 2770/32471 Demonstrated *in vivo* effect
- 2770/32488 For redistribution
- 2770/32511 Parechovirus, e.g. human parechovirus
- 2770/32521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32523 Virus like particles [VLP]
- 2770/32531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32541 Use of virus, viral particle or viral elements as a vector
- 2770/32542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32543 viral genome or elements thereof as genetic vector

- 2770/32544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32545 Special targeting system for viral vectors
- 2770/32551 Methods of production or purification of viral material
- 2770/32552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32561 Methods of inactivation or attenuation
- 2770/32562 by genetic engineering
- 2770/32563 by chemical treatment
- 2770/32564 by serial passage
- 2770/32571 Demonstrated *in vivo* effect
- 2770/32588 For redistribution
- 2770/32611 . . . Poliovirus
- 2770/32621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32623 Virus like particles [VLP]
- 2770/32631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32641 Use of virus, viral particle or viral elements as a vector
- 2770/32642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32643 viral genome or elements thereof as genetic vector
- 2770/32644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32645 Special targeting system for viral vectors
- 2770/32651 Methods of production or purification of viral material
- 2770/32652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32661 Methods of inactivation or attenuation
- 2770/32662 by genetic engineering
- 2770/32663 by chemical treatment
- 2770/32664 by serial passage
- 2770/32671 Demonstrated *in vivo* effect
- 2770/32688 For redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 Virus like particles [VLP]
- 2770/32731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 Use of virus, viral particle or viral elements as a vector
- 2770/32742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 viral genome or elements thereof as genetic vector
- 2770/32744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 Special targeting system for viral vectors
- 2770/32751 Methods of production or purification of viral material
- 2770/32752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 Methods of inactivation or attenuation
- 2770/32762 by genetic engineering
- 2770/32763 by chemical treatment
- 2770/32764 by serial passage
- 2770/32771 Demonstrated *in vivo* effect
- 2770/32788 For redistribution
- 2770/34011 . . . Potyviridae
- 2770/34021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 Virus like particles [VLP]
- 2770/34031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 Use of virus, viral particle or viral elements as a vector
- 2770/34042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 viral genome or elements thereof as genetic vector
- 2770/34044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 Special targeting system for viral vectors
- 2770/34051 Methods of production or purification of viral material
- 2770/34052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 Methods of inactivation or attenuation
- 2770/34062 by genetic engineering
- 2770/34063 by chemical treatment
- 2770/34064 by serial passage
- 2770/34071 Demonstrated *in vivo* effect

- 2770/34088 . . . For redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 viral genome or elements thereof as genetic vector
- 2770/36044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 by genetic engineering
- 2770/36063 by chemical treatment
- 2770/36064 by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . For redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 Virus like particles [VLP]
- 2770/36131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 Use of virus, viral particle or viral elements as a vector
- 2770/36142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 viral genome or elements thereof as genetic vector
- 2770/36144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 Special targeting system for viral vectors
- 2770/36151 Methods of production or purification of viral material
- 2770/36152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 Methods of inactivation or attenuation
- 2770/36162 by genetic engineering
- 2770/36163 by chemical treatment
- 2770/36164 by serial passage
- 2770/36171 Demonstrated in vivo effect
- 2770/36188 For redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 Virus like particles [VLP]
- 2770/36231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 Use of virus, viral particle or viral elements as a vector
- 2770/36242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 viral genome or elements thereof as genetic vector
- 2770/36244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 Special targeting system for viral vectors
- 2770/36251 Methods of production or purification of viral material
- 2770/36252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 Methods of inactivation or attenuation
- 2770/36262 by genetic engineering
- 2770/36263 by chemical treatment
- 2770/36264 by serial passage
- 2770/36271 Demonstrated in vivo effect
- 2770/36288 For redistribution
- 2770/38011 . . . Tombusviridae
- 2770/38021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 . . . Virus like particles [VLP]
- 2770/38031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/38033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/38042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 viral genome or elements thereof as genetic vector
- 2770/38044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 Special targeting system for viral vectors
- 2770/38051 . . . Methods of production or purification of viral material
- 2770/38052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 . . . Methods of inactivation or attenuation
- 2770/38062 by genetic engineering
- 2770/38063 by chemical treatment
- 2770/38064 by serial passage
- 2770/38071 . . . Demonstrated in vivo effect
- 2770/38088 . . . For redistribution
- 2770/40011 . . Tymoviridae
- 2770/40021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . Virus like particles [VLP]
- 2770/40031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 viral genome or elements thereof as genetic vector
- 2770/40044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 Special targeting system for viral vectors
- 2770/40051 . . . Methods of production or purification of viral material
- 2770/40052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . Methods of inactivation or attenuation
- 2770/40062 by genetic engineering
- 2770/40063 by chemical treatment
- 2770/40064 by serial passage
- 2770/40071 . . . Demonstrated in vivo effect
- 2780/40088 . . . For redistribution
- 2780/00** **Naked RNA Viruses (not used)**
- 2780/00011 . Naked RNA Viruses
- 2780/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . Virus like particles [VLP]
- 2780/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . For redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 viral genome or elements thereof as genetic vector

- 2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 Special targeting system for viral vectors
- 2780/10051 Methods of production or purification of viral material
- 2780/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 Methods of inactivation or attenuation
- 2780/10062 by genetic engineering
- 2780/10063 by chemical treatment
- 2780/10064 by serial passage
- 2780/10071 Demonstrated in vivo effect
- 2780/10088 For redistribution
- 2790/00** **Viroids and subviral agents (not used)**
- 2790/00011 . . . Viroids and subviral agents
- 2790/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . . Virus like particles [VLP]
- 2790/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 viral genome or elements thereof as genetic vector
- 2790/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 Special targeting system for viral vectors
- 2790/00051 Methods of production or purification of viral material
- 2790/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 Methods of inactivation or attenuation
- 2790/00062 by genetic engineering
- 2790/00063 by chemical treatment
- 2790/00064 by serial passage
- 2790/00071 Demonstrated in vivo effect
- 2790/00088 For redistribution
- 2790/10011 . . . Prions
- 2790/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 Virus like particles [VLP]
- 2790/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 Use of virus, viral particle or viral elements as a vector
- 2790/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 viral genome or elements thereof as genetic vector
- 2790/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 Special targeting system for viral vectors
- 2790/10051 Methods of production or purification of viral material
- 2790/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 Methods of inactivation or attenuation
- 2790/10062 by genetic engineering
- 2790/10063 by chemical treatment
- 2790/10064 by serial passage
- 2790/10071 Demonstrated in vivo effect
- 2790/10088 For redistribution
- 2790/12011 Satellite viruses
- 2790/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 Virus like particles [VLP]
- 2790/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 Use of virus, viral particle or viral elements as a vector
- 2790/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 viral genome or elements thereof as genetic vector
- 2790/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 Special targeting system for viral vectors
- 2790/12051 Methods of production or purification of viral material
- 2790/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 Methods of inactivation or attenuation
- 2790/12062 by genetic engineering
- 2790/12063 by chemical treatment

- 2790/12064 by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . For redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 viral genome or elements thereof as genetic vector
- 2790/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 by genetic engineering
- 2790/14063 by chemical treatment
- 2790/14064 by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . For redistribution
- 2792/00** **Archaeobacteria viruses (not used)**
- 2792/00011 . Archaeobacteria viruses
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]
- 2792/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 Special targeting system for viral vectors
- 2792/00051 . . . Methods of production or purification of viral material
- 2792/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . . Methods of inactivation or attenuation
- 2792/00062 by genetic engineering
- 2792/00063 by chemical treatment
- 2792/00064 by serial passage
- 2792/00071 . . . Demonstrated in vivo effect
- 2792/00088 . . . For redistribution
- 2792/10011 . . Fuselloviridae
- 2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . Virus like particles [VLP]
- 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 viral genome or elements thereof as genetic vector
- 2792/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 Special targeting system for viral vectors
- 2792/10051 . . . Methods of production or purification of viral material
- 2792/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . Methods of inactivation or attenuation
- 2792/10062 by genetic engineering
- 2792/10063 by chemical treatment
- 2792/10064 by serial passage
- 2792/10071 . . . Demonstrated in vivo effect
- 2792/10088 . . . For redistribution
- 2792/12011 . . Guttaviridae
- 2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . Virus like particles [VLP]
- 2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 viral genome or elements thereof as genetic vector
- 2792/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 Special targeting system for viral vectors
- 2792/12051 . . . Methods of production or purification of viral material
- 2792/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . Methods of inactivation or attenuation
- 2792/12062 by genetic engineering
- 2792/12063 by chemical treatment
- 2792/12064 by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . For redistribution
- 2795/00 Bacteriophages (not used)**
- 2795/00011 . Bacteriophages
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . . Demonstrated in vivo effect
- 2795/00088 . . . For redistribution
- 2795/01011 . . . Myoviridae
- 2795/01021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/01022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/01023 Virus like particles [VLP]
- 2795/01031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/01032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/01033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/01034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/01041 Use of virus, viral particle or viral elements as a vector
- 2795/01042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2795/10143 viral genome or elements thereof as genetic vector
- 2795/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 Special targeting system for viral vectors
- 2795/10151 Methods of production or purification of viral material
- 2795/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 Methods of inactivation or attenuation
- 2795/10162 by genetic engineering
- 2795/10163 by chemical treatment
- 2795/10164 by serial passage
- 2795/10171 Demonstrated in vivo effect
- 2795/10188 For redistribution
- 2795/10211 Podoviridae
- 2795/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 Virus like particles [VLP]
- 2795/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 Use of virus, viral particle or viral elements as a vector
- 2795/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 viral genome or elements thereof as genetic vector
- 2795/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 Special targeting system for viral vectors
- 2795/10251 Methods of production or purification of viral material
- 2795/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 Methods of inactivation or attenuation
- 2795/10262 by genetic engineering
- 2795/10263 by chemical treatment
- 2795/10264 by serial passage
- 2795/10271 Demonstrated in vivo effect
- 2795/10288 For redistribution
- 2795/10311 Siphoviridae
- 2795/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 Virus like particles [VLP]
- 2795/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 Use of virus, viral particle or viral elements as a vector
- 2795/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 viral genome or elements thereof as genetic vector
- 2795/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 Special targeting system for viral vectors
- 2795/10351 Methods of production or purification of viral material
- 2795/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 Methods of inactivation or attenuation
- 2795/10362 by genetic engineering
- 2795/10363 by chemical treatment
- 2795/10364 by serial passage
- 2795/10371 Demonstrated in vivo effect
- 2795/10388 For redistribution
- 2795/12011 . . . dsRNA Bacteriophages
- 2795/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . Virus like particles [VLP]
- 2795/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 . . . viral genome or elements thereof as genetic vector
- 2795/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 . . . Special targeting system for viral vectors
- 2795/12051 . . . Methods of production or purification of viral material
- 2795/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 . . . Methods of inactivation or attenuation
- 2795/12062 . . . by genetic engineering
- 2795/12063 . . . by chemical treatment

- 2795/12064 by serial passage
- 2795/12071 . . . Demonstrated in vivo effect
- 2795/12088 . . . For redistribution
- 2795/14011 . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 viral genome or elements thereof as genetic vector
- 2795/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 Special targeting system for viral vectors
- 2795/14051 . . . Methods of production or purification of viral material
- 2795/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 . . . Methods of inactivation or attenuation
- 2795/14062 by genetic engineering
- 2795/14063 by chemical treatment
- 2795/14064 by serial passage
- 2795/14071 . . . Demonstrated in vivo effect
- 2795/14088 . . . For redistribution
- 2795/14111 . . . Inoviridae
- 2795/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 Virus like particles [VLP]
- 2795/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 Use of virus, viral particle or viral elements as a vector
- 2795/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 viral genome or elements thereof as genetic vector
- 2795/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 Special targeting system for viral vectors
- 2795/14151 Methods of production or purification of viral material
- 2795/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 Methods of inactivation or attenuation
- 2795/14162 by genetic engineering
- 2795/14163 by chemical treatment
- 2795/14164 by serial passage
- 2795/14171 Demonstrated in vivo effect
- 2795/14188 For redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 Virus like particles [VLP]
- 2795/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 Use of virus, viral particle or viral elements as a vector
- 2795/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 viral genome or elements thereof as genetic vector
- 2795/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 Special targeting system for viral vectors
- 2795/14251 Methods of production or purification of viral material
- 2795/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 Methods of inactivation or attenuation
- 2795/14262 by genetic engineering
- 2795/14263 by chemical treatment
- 2795/14264 by serial passage
- 2795/14271 Demonstrated in vivo effect
- 2795/14288 For redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2795/16033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/16034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/16041	. . .	Use of virus, viral particle or viral elements as a vector
2795/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/16043	viral genome or elements thereof as genetic vector
2795/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/16045	Special targeting system for viral vectors
2795/16051	. . .	Methods of production or purification of viral material
2795/16052	relating to complementing cells and packaging systems for producing virus or viral particles
2795/16061	. . .	Methods of inactivation or attenuation
2795/16062	by genetic engineering
2795/16063	by chemical treatment
2795/16064	by serial passage
2795/16071	. . .	Demonstrated <u>in vivo</u> effect
2795/16088	. . .	For redistribution
2795/18011	. .	ssRNA Bacteriophages positive-sense
2795/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/18023	. . .	Virus like particles [VLP]
2795/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/18041	. . .	Use of virus, viral particle or viral elements as a vector
2795/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/18043	viral genome or elements thereof as genetic vector
2795/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18045	Special targeting system for viral vectors
2795/18051	. . .	Methods of production or purification of viral material
2795/18052	relating to complementing cells and packaging systems for producing virus or viral particles
2795/18061	. . .	Methods of inactivation or attenuation
2795/18062	by genetic engineering
2795/18063	by chemical treatment
2795/18064	by serial passage
2795/18071	. . .	Demonstrated <u>in vivo</u> effect
2795/18088	. . .	For redistribution
2795/18111	. . .	Leviviridae
2795/18121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/18122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/18123	Virus like particles [VLP]
2795/18131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/18132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/18133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/18134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/18141	Use of virus, viral particle or viral elements as a vector
2795/18142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/18143	viral genome or elements thereof as genetic vector
2795/18144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18145	Special targeting system for viral vectors
2795/18151	Methods of production or purification of viral material
2795/18152	relating to complementing cells and packaging systems for producing virus or viral particles
2795/18161	Methods of inactivation or attenuation
2795/18162	by genetic engineering
2795/18163	by chemical treatment
2795/18164	by serial passage
2795/18171	Demonstrated <u>in vivo</u> effect
2795/18188	For redistribution
2799/00		Uses of viruses
		<u>WARNING</u>
		From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00-C12N 2795/00
2799/02	. .	as vector
2799/021	. .	for the expression of a heterologous nucleic acid
2799/022	. . .	where the vector is derived from an adenovirus
2799/023	. . .	where the vector is derived from a poxvirus
2799/025	. . .	where the vector is derived from a parvovirus
2799/026	. . .	where the vector is derived from a baculovirus
2799/027	. . .	where the vector is derived from a retrovirus
2799/028	. . .	where the vector is derived from a herpesvirus
2799/04	. .	<u>in vivo</u>
2799/06	. .	<u>in vitro</u>
2800/00		Nucleic acids vectors
2800/10	. .	Plasmid DNA
2800/101	. .	for bacteria
2800/102	. .	for yeast

- 2800/103 . . for invertebrates
- 2800/105 . . . for insects
- 2800/106 . . for vertebrates
- 2800/107 . . . for mammalian
- 2800/108 . . episomal vectors
- 2800/20 . Pseudochromosomes, minichromosomes
- 2800/202 . . of bacteriophage origin
- 2800/204 . . of bacterial origin, e.g. BAC
- 2800/206 . . of yeast origin, e.g. YAC, 2u
- 2800/208 . . of mammalian origin, e.g. minichromosome
- 2800/22 . Vectors comprising a coding region that has been codon optimised for expression in a respective host
- 2800/24 . Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- 2800/30 . Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- 2800/40 . Systems of functionally co-operating vectors
- 2800/50 . Vectors for producing vectors
- 2800/60 . Vectors containing traps for, e.g. exons, promoters
- 2800/70 . Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- 2800/80 . Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- 2800/90 . Vectors containing a transposable element
- 2800/95 . Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
- 2810/00 Vectors comprising a targeting moiety**
- 2810/10 . Vectors comprising a non-peptidic targeting moiety
- 2810/40 . Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- 2810/405 . . Vectors comprising RGD peptide
- 2810/50 . Vectors comprising as targeting moiety peptide derived from defined protein
- 2810/55 . . from bacteria
- 2810/60 . . from viruses
- 2810/6009 . . . dsDNA viruses
- 2810/6018 Adenoviridae
- 2810/6027 . . . ssDNA viruses
- 2810/6036 . . . DNA rev transcr viruses
- 2810/6045 . . . RNA rev transcr viruses
- 2810/6054 Retroviridae
- 2810/6063 . . . ds RNA viruses
- 2810/6072 . . . negative strand RNA viruses
- 2810/6081 rhabdoviridae, e.g. VSV
- 2810/609 . . . positive strand RNA viruses
- 2810/65 . . from plants
- 2810/70 . . from fungi
- 2810/75 . . from invertebrates
- 2810/80 . . from vertebrates
- 2810/85 . . . mammalian
- 2810/851 from growth factors; from growth regulators
- 2810/852 from cytokines; from lymphokines; from interferons
- 2810/853 from tumor necrosis factor, TNF
- 2810/854 from hormones
- 2810/855 from receptors; from cell surface antigens; from cell surface determinants
- 2810/856 from integrins
- 2810/857 from blood coagulation or fibrinolysis factors
- 2810/858 from apolipoproteins
- 2810/859 from immunoglobulins
- 2810/90 . . . avian
- 2820/00 Vectors comprising a special origin of replication system**
- 2820/002 . inducible or controllable
- 2820/005 . cell-cycle regulated
- 2820/007 . tissue or cell-specific
- 2820/10 . multiple origins of replication
- 2820/55 . from bacteria
- 2820/60 . from viruses
- 2820/65 . from plants
- 2820/70 . from fungi
- 2820/702 . . yeast
- 2820/704 . . . S. cerevisiae
- 2820/706 . . . S. pombe
- 2820/708 . . . C. albicans
- 2820/75 . from invertebrates
- 2820/80 . from vertebrates
- 2820/85 . . mammalian
- 2820/90 . . avian
- 2830/00 Vector systems having a special element relevant for transcription**
- 2830/001 . controllable enhancer/promoter combination
- 2830/002 . . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- 2830/003 . . . tet inducible
- 2830/005 . . repressible enhancer/promoter combination, e.g. KRAB
- 2830/006 . . . tet repressible
- 2830/007 . cell cycle specific enhancer/promoter combination
- 2830/008 . cell type or tissue specific enhancer/promoter combination
- 2830/15 . chimeric enhancer/promoter combination
- 2830/20 . transcription of more than one cistron
- 2830/205 . . bidirectional
- 2830/30 . being an enhancer not forming part of the promoter region
- 2830/32 . being an silencer not forming part of the promoter region
- 2830/34 . being a transcription initiation element
- 2830/36 . being a transcription termination element
- 2830/38 . being a stuffer
- 2830/40 . being an insulator
- 2830/42 . being an intron or intervening sequence for splicing and/or stability of RNA
- 2830/46 . elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- 2830/48 . regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- 2830/50 . regulating RNA stability, not being an intron, e.g. poly A signal
- 2830/52 . encoding ribozyme for self-inactivation
- 2830/55 . from bacteria
- 2830/60 . from viruses
- 2830/65 . from plants
- 2830/70 . from fungi
- 2830/702 . . yeast
- 2830/704 . . . S. cerevisiae
- 2830/706 . . . S. pombe
- 2830/708 . . . C. albicans
- 2830/75 . from invertebrates

- 2830/80 . from vertebrates
- 2830/85 . . mammalian
- 2830/90 . . avian

2840/00 Vectors comprising a special translation-regulating system

- 2840/002 . controllable or inducible
- 2840/005 . cell cycle specific
- 2840/007 . cell or tissue specific
- 2840/10 . regulates levels of translation
- 2840/102 . . inhibiting translation
- 2840/105 . . enhancing translation
- 2840/107 . . inhibiting translational read-through
- 2840/20 . translation of more than one cistron
- 2840/203 . . having an IRES
- 2840/206 . . . having multiple IRES
- 2840/44 . being a specific part of the splice mechanism, e.g. donor, acceptor
- 2840/445 . . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- 2840/50 . utilisation of non-ATG initiation codon

NOTE

This groups covers artificial modification only,
i.e. naturally occurring use of non-ATG start
codon is not classified here

- 2840/55 . from bacteria
- 2840/60 . from viruses
- 2840/65 . from plants
- 2840/70 . from fungi
- 2840/702 . . yeast
- 2840/704 . . . S. cerevisiae
- 2840/706 . . . S. pombe
- 2840/708 . . . C. albicans
- 2840/75 . from invertebrates
- 2840/80 . from vertebrates
- 2840/85 . . mammalian
- 2840/90 . . avian

2999/00 Further aspects of viruses or vectors not covered by the [C12N 2700/00](#) or [C12N 2800/00](#) series

NOTES

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

- 2999/002 . Adverse teaching
- 2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- 2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals